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Development and optimization of production and purification of 
the human protein BMP-2 in Escherichia coli for biomedical 
applications 
Abstract  
 
Bone morphogenetic protein 2 (BMP-2) is one of the main representatives 
osteoinductive protein of a group of the transforming growth factor-β (TGF-β) 
superfamily of multifunctional cytokines. BMP-2 plays a critical role in cartilage and 
bone formation during skeletal development and repair. Several clinical studies have 
proven the clinical benefit of BMP-2 in the treatment of bone defects, being an effective 
alternative to bone grafts. Nowadays, BMP-2 is one of the two bone morphogenetic 
proteins approved as biological method to stimulate bone repair in humans. However, 
these commercial solutions are expensive, the protein purification is a laborious process 
and the obtained yields are low. 
A landmark occurred with the cloning of the human BMP-2 gene and its 
production by DNA recombinant technology. Production of recombinant human BMP-
2, using prokaryotic systems is the preferred method, being Escherichia coli one of the 
most popular systems for protein production. The bacterium E. coli is a well studied 
expression system, which provides a fast and economical production of recombinant 
proteins. Various studies on the production and purification of BMP-2 protein using E. 
coli as expression system have been reported; however BMP-2 is difficult to express in 
soluble form and its purification under native conditions remains a challenge. 
In this work, the soluble expression of the recombinant BMP-2 protein in E. coli 
was studied using the fusion protein technology, with the novel FH8 tag.  
The production of soluble recombinant fusion protein was initially achieved 
using as backbone the pQE-30FH8 vector, with the study of different culture conditions, 
in order to determine the conditions that maximize this soluble expression. Then, in 
order to increase soluble expression of FH8BMP-2, the cloning of bmp-2 gene was 
performed in two other different vectors: the pETMFH8 and pStaby1.2FH8, using 
different E. coli strains. Purification strategy of FH8BMP-2 was performed by the 
following chromatography techniques: using the FH8 as purification tag by 
hydrophobic interaction (HIC); affinity chromatography with nickel (using the His tag 
as purification tag) and ion exchange. 
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The results presented in this work showed that recombinant fusion protein was 
successfully soluble expressed in the three vectors used. The pETM system was the one 
that showed the highest soluble expression. In relation to purification, the FH8-HIC 
technique, when combined with calcium addition to soluble fraction, shows good results 
in purification profile of target protein and a high yield of purified protein. Calcium ions 
and the own conformation of FH8 can have an important role on the aggregation of 
FH8BMP-2 into a dimer.  
Overall, the BMP-2 was efficiently expressed in E. coli as a soluble protein and 
an optimized purification strategy was developed to obtain this bone morphogenetic 
protein under native conditions. 
This work may be important for further steps for an in vitro production and 
biomedical application of recombinant BMP-2 protein. 
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Desenvolvimento e otimização da produção e purificação da 
proteína humana BMP-2 em Escherichia coli para aplicações 
biomédicas 
Sumário  
 
A proteína morfogenética do osso tipo 2 (BMP-2) é uma das proteínas 
osteoindutoras mais representativas da superfamília do fator de transformação do 
crescimento β (TGF-β) que agrupa um conjunto de citoquinas multifuncionais. A 
proteína BMP-2 desempenha um papel crítico na formação e regeneração do osso e 
cartilagem, durante o desenvolvimento do esqueleto. Vários estudos clínicos têm 
demonstrado o benefício clínico da BMP-2 no tratamento de defeitos ósseos, sendo uma 
alternativa eficaz aos enxertos do osso. Atualmente, a BMP-2 é uma das duas proteínas 
morfogenéticas do osso que se encontra aprovada como método biológico para 
estimular a reparação óssea em seres humanos. No entanto, estas soluções comerciais 
são dispendiosas, a purificação da proteína é um processo laborioso e os rendimentos 
obtidos são baixos. 
Um marco importante ocorreu com a clonagem do gene humano da proteína 
BMP-2 e a sua produção através da tecnologia de DNA recombinante. A produção desta 
proteína humana recombinante, utilizando os sistemas procarióticos é o método 
preferido, sendo a bactéria Escherichia coli um dos sistemas mais populares de 
produção proteica. A bactéria E. coli é um sistema de expressão bem estudado, que 
proporciona uma produção rápida e económica de proteínas recombinantes de interesse. 
Vários estudos têm reportado a produção e purificação da proteína BMP-2, usando 
como sistema de expressão a E. coli; contudo, a proteína BMP-2 é difícil de expressar 
na forma solúvel e sua purificação em condições nativas continua a ser um desafio. 
Neste trabalho, a expressão solúvel da proteína BMP-2 recombinante em E.coli 
foi estudada através da tecnologia de proteínas de fusão, com o novo tag de fusão FH8.  
A produção solúvel da proteína de fusão recombinante foi conseguida usando 
como vetor inicial o pQE-30FH8, com o estudo das diferentes condições de cultura, 
com o objetivo de determinar as condições que maximizam essa expressão solúvel. Em 
seguida, com a finalidade de aumentar a expressão solúvel da FH8BMP-2, foi realizada 
a clonagem do gene da BMP-2 em dois vetores diferentes: o pETMFH8 e 
pStaby1.2FH8, usando diferentes estirpes de E. coli. A estratégia de purificação da 
 vi 
 
proteína FH8BMP-2 envolveu a realização das seguintes técnicas de cromatografia: 
interação hidrofóbica (HIC), usando o tag FH8 como tag de purificação; cromatografia 
de afinidade com níquel (usando o His tag como tag de purificação) e troca iónica. 
Os resultados apresentados neste trabalho mostraram que a proteína de fusão 
recombinante foi expressa solúvel com sucesso nos três vetores utilizados. O sistema 
pETM foi aquele que apresentou um maior nível de expressão solúvel. Em relação à 
purificação, a técnica de FH8-HIC, quando combinada com a adição de cálcio à fração 
solúvel, apresenta bons resultados em relação ao perfil de purificação da proteína alvo e 
um elevado rendimento de proteína purificada foi obtido. Os iões de cálcio e a própria 
conformação do tag FH8 podem ter um importante papel na agregação da FH8BMP-2 
na forma dimérica. 
Em geral, a BMP-2 foi eficientemente expressa no sistema E. coli como proteína 
solúvel e uma estratégia de purificação otimizada foi delineada para obter esta proteína 
morfogenética do osso em condições nativas. 
Este trabalho pode ser importante para novas etapas de uma produção in vitro e 
aplicação biomédica da proteína BMP-2 recombinante. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
Table of Contents 
 
Acknowledgments ............................................................................................................. i 
Abstract ............................................................................................................................ iii 
Sumário ............................................................................................................................. v 
List of Figures .................................................................................................................. xi 
List of Tables ................................................................................................................. xiii 
Abbreviations ................................................................................................................. xv 
 
Motivation and aim of the project................................................................................. 1 
 
Chapter 1: Review Literature ....................................................................................... 3 
1.1 Bone morphogenetic proteins ................................................................................. 3 
1.1.1 Bone morphogenetic protein 2 (BMP-2) .......................................................... 4 
1.2 Commercial BMP2 ................................................................................................. 5 
1.3 Recombinant production of BMP-2 ........................................................................ 6 
1.3.1 E. coli as a host ................................................................................................. 7 
1.4 Production of soluble recombinant BMP-2 ............................................................ 8 
1.4.1 Fusion Protein Technology .............................................................................. 9 
1.4.1.1 Fusion system – FH8 tag ......................................................................... 10 
 
Chapter 2: Materials and Methods ............................................................................. 13 
2.1 Sterilization of material, culture media and solutions .......................................... 13 
2.2 Chemical products, solutions and reagentes ......................................................... 13 
2.3 Vectors and Bacterial strains ................................................................................ 13 
2.3.1 pQE-30 QIAexpress system ........................................................................... 14 
2.3.2 pETM vector .................................................................................................. 14 
2.3.3 pStaby1.2 Express System ............................................................................. 15 
2.4 Molecular Biological Methods ............................................................................. 16 
2.4.1 Extraction of plasmid DNA and template sequence of BMP-2 from E. coli . 16 
2.4.2 PCR of insert fragment – bmp-2 gene ............................................................ 16 
2.4.3 Agarose Gel Electrophoresis .......................................................................... 18 
2.4.4 DNA purification............................................................................................ 18 
2.4.5 Digestion of DNA with restriction enzymes .................................................. 18 
2.4.6 Dephosphorylation of Plasmid DNA ............................................................. 19 
2.4.7 DNA quantification ........................................................................................ 19 
2.4.8 Ligation of DNA insert fragment to the vector .............................................. 19 
2.4.9 Preparation of chemical competent E. coli cells ............................................ 20 
2.4.10 Transformation of recombinant DNA to competent E. coli cells ................ 20 
2.4.10.1 Transformation of chemically competent DH5α E. coli cells ............... 20 
2.4.10.2 Transformation of chemically competent Top 10 E. coli cells .............. 21 
2.4.11 Screening of Transformants ......................................................................... 21 
 viii 
 
2.4.12 DNA Sequencing.......................................................................................... 22 
2.4.13 Transformation of chemically competent BL21 Codon Plus Ril and Rosetta 
2 E. coli cells ........................................................................................................... 22 
2.4.14 Transformation of chemically competent SE1 E. coli cells ......................... 22 
2.5 Soluble Expression of recombinant FH8BMP-2 protein in E. coli ...................... 22 
2.5.1 Study of the soluble expression conditions of recombinant FH8BMP-2 
protein in E. coli M15/pQE-30 ................................................................................ 23 
2.5.2 Soluble expression of recombinant FH8BMP-2 protein in E.coli M15 /pQE30
 ................................................................................................................................. 24 
2.5.3 Study of the soluble expression conditions of recombinant FH8BMP-2 
protein in pETM: E. coli BL21 Codon Plus Ril and Rosetta2 ................................ 24 
2.5.4 Soluble expression of recombinant FH8BMP-2 protein in E. coli BL21 Ril 
/pETM10 ................................................................................................................. 25 
2.5.5 Conditions study of soluble expression of recombinant FH8BMP-2 protein in 
E. coli SE1/pStaby1.2.............................................................................................. 25 
2.6 Electrophoresis under denaturing conditions: SDS-PAGE................................... 26 
2.7 Purification of recombinant FH8BMP-2 protein .................................................. 27 
2.7.1 Hydrophobic Interaction Chromatography (HIC) .......................................... 27 
2.7.1.1 Small scale screenings protocol ............................................................... 30 
2.7.1.2 0.5-1L Purification Assays protocol ........................................................ 31 
2.7.2 Immobilized metal ion Affinity Chromatography (IMAC) ........................... 32 
2.7.2.1 Small scale screenings protocol ............................................................... 33 
2.7.2.2 0.5-1L Purification Assays protocol ........................................................ 34 
2.7.3 Ion Exchange (IEX) chromatography ............................................................ 34 
2.8 Protein dialysis ...................................................................................................... 36 
2.9 Protein quantification ............................................................................................ 36 
2.10 Dynamic light scattering (DLS) .......................................................................... 37 
 
Chapter 3: Results and Discussion .............................................................................. 39 
3.1 Soluble expression and purification of recombinant FH8BMP-2 in E. coli using 
the pQE-30 system ...................................................................................................... 39 
3.1.1 Soluble test expression of recombinant FH8BMP-2 in E. coli M15 using the 
pQE-30 system ........................................................................................................ 39 
3.1.2 Small screening purification test of soluble recombinant FH8BMP-2 
produced in E. coli M15 using the pQE-30 system................................................. 43 
3.1.3Larger scale purification test of soluble recombinant FH8BMP-2 in E. coli 
M15 using the pQE-30 system ................................................................................ 46 
3.2 Cloning of bmp-2 gene into pETMFH8 and pStaby1.2FH8 plasmids ................. 49 
3.3 Soluble expression and purification of recombinant FH8BMP-2 in E. coli using 
pETMFH8 and pStaby1.2FH8 systems ...................................................................... 53 
3.3.1 Small scale screening ..................................................................................... 53 
3.4 Larger scale production and purification tests of soluble recombinant FH8BMP-2 
in E. coli using pETM system ..................................................................................... 57 
3.4.1 Immobilized nickel ion affinity chromatography (IMAC-Ni) ....................... 57 
 ix 
 
3.4.2 Hydrophobic interaction chromatography ..................................................... 58 
3.4.2.1 Optimization of HIC wash step ............................................................... 62 
3.4.3 Ion exchange chromatography ....................................................................... 65 
3.5 Larger scale production and purification tests of soluble recombinant FH8BMP-2 
in pStaby1.2 system .................................................................................................... 67 
 
Chapter 4: Main Conclusions and suggestions for forthcoming work .................... 69 
 
Chapter 5: Reference List ............................................................................................ 71 
 
Chapter 6: Appendixes ................................................................................................. 77 
Appendix 1: Detailed composition of chemical products, solutions and reagents ..... 77 
Appendix 2: Hidrophobicity analysis of FH8BMP-2 using Kyte and Doolittle scale 78 
Appendix 3: Neb-Cutter analysis ................................................................................ 79 
Appendix 4: BLASTN analysis of the sequencing results of pETM/FH8BMP-2 and 
pStaby1.2/FH8BMP-2 clones ..................................................................................... 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
 
List of Figures 
 
Figure 1: Activation of BMP dimer .................................................................................. 4 
Figure 2: Gene transcription by BMP-Smad activation ................................................... 4 
Figure 3: a) Model structure of FH8 in the closed conformation (yellow). After calcium 
ligation occur a change to open conformation (green) and on the right is possible to see 
in detail the calcium binding loops, where calcium ions are represented by grey spheres. 
b) Molecular surface representation of FH8 in closed (left) and open (right) 
conformations ................................................................................................................. 11 
Figure 4: Graphic of plasmid map of pQE-30, Qiagen .................................................. 14 
Figure 5: Graphic of plasmid map of pETMFH8, EMBL .............................................. 15 
Figure 6: Graphic of plasmid map of pStaby1.2FH8, Delphi ........................................ 16 
Figure 7: Soluble expression conditions of FH8BMP-2 in pQE system ........................ 23 
Figure 8: Variation of surface net charge according to pH of the medium .................... 34 
Figure 9: a) 15%-4% SDS-PAGE solubility analysis of BMP-2 in pQE-30 system; b) 
15%-4% SDS-PAGE solubility analysis of HBMP-2 in pQE-30 system ...................... 40 
Figure 10: 15%-4% SDS PAGE analysis of expression level of recombinant FH8BMP-2 
in E. coli M15/pQE-30 ................................................................................................... 41 
Figure 11: SDS-PAGE Solubility analysis of FH8BMP-2 in pQE-30 system of 250 ml 
cultures  .......................................................................................................................... 42 
Figure 12: 15%-4% SDS-PAGE analysis of samples obtained from HIC small scale 
purification assays of FH8BMP-2: ................................................................................. 44 
Figure 13: 15%-4% SDS-PAGE analysis of samples obtained from IMAC-Ni small 
scale purification assay ................................................................................................... 45 
Figure 14: HIC purification assay of 1L E. coli M15/pQE-30 culture of FH8BMP-2 .. 47 
Figure 15: Second HIC purification of eluted samples of first HIC assay containing 
recombinant FH8BMP-2 ................................................................................................ 48 
Figure 16: Cloning strategy to pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2 constructs
 ........................................................................................................................................ 50 
Figure 17: 1% Agarose electrophoresis analysis of bmp-2 PCR products ..................... 51 
Figure 18: 1% Agarose electrophoresis analysis of DNA plasmids ............................... 52 
Figure 19: 1.2% Agarose electrophoresis analysis of transformants of recombinant 
vectors: a) Transformants of pETMFH8BMP-2; b) Transformants of 
pStaby1.2FH8BMP-2 ..................................................................................................... 53 
 xii 
 
Figure 20: 15%-4% SDS-PAGE solubility analysis of FH8BMP-2 in pETM system in 
20 ml cultures: a) E. coli BL21 Codon plus Ril culture; b) E. coli Rosetta 2 culture .... 54 
Figure 21: 15%-4% SDS-PAGE solubility analysis of pETM/FH8BMP-2; 
pETM/HisBMP-2; pETM/FH8 and pETM/His samples ................................................ 55 
Figure 22: 15%-4% SDS-PAGE Solubility analysis of FH8BMP-2 in pStaby1.2 system 
in E. coli SE1 20 ml cultures in comparison with pStaby1.2/FH8 (negative control –
without protein) .............................................................................................................. 56 
Figure 23: 15%-4% SDS-PAGE analysis of samples obtained from IMAC-Ni small 
scale purification assay: .................................................................................................. 58 
Figure 24: 15%-4% SDS-PAGE gel with samples of 1L of E. coli BL21 Codon plus Ril 
culture of FH8BMP-2 and HIC purification samples ..................................................... 59 
Figure 25: 15%-4% SDS-PAGE gel with HIC purification samples from 1L of E. coli 
BL21Codon plus Ril culture of FH8BMP-2, with lower calcium concentration ........... 60 
Figure 26: 15%-4% SDS-PAGE gel with samples of second HIC purification performed 
with eluted samples obtained from first HIC purification assay .................................... 61 
Figure 27: 15%-4% SDS-PAGE gel with samples of HIC purification performed with 
different wash buffers ..................................................................................................... 64 
Figure 28: 15%-4% SDS-PAGE gel with samples of HIC purification performed with 
wash buffers W0 and W1 ............................................................................................... 64 
Figure 29: Illustrative diagram of steps performed in IEX procedure. .......................... 65 
 
Figure A1: Analysis of the hydrophobicity of pQE-30/FH8BMP-2, according to the 
Kyte and Doolittle scale. ................................................................................................ 78 
Figure A2: Analysis of the hydrophobicity of pETM/FH8BMP-2, according to the Kyte 
and Doolittle scale .......................................................................................................... 79 
Figure A3: BLASTN analysis of pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2 clones
 ........................................................................................................................................ 80 
Figure A4: Results of the analysis of protein domains in fusion conserved domain by 
NCBI software. ............................................................................................................... 81 
 
 
 xiii 
 
List of Tables 
 
Table 1: Selected works reporting the production of rhBMP-2 in different expression 
systems ............................................................................................................................. 6 
Table 2: Studies of the production and purification of rhBMP-2 in E.coli. ..................... 8 
Table 3: Commonly used solubility fusion tags ............................................................. 10 
Table 4: Plasmid vectors and bacterial strains used in the present work. ...................... 13 
Table 5: Sequence of primers used in PCR reaction. ..................................................... 17 
Table 6: PCR program. ................................................................................................... 17 
Table 7: Description of restriction enzymes used. ......................................................... 19 
Table 8: Colony PCR program. ...................................................................................... 22 
Table 9: SDS-PAGE gels composition. .......................................................................... 26 
Table 10: Buffers recipe for FH8-HIC small screenings. ............................................... 29 
Table 11: Buffers recipe for FH8-HIC 0.5-1L purification assays................................. 29 
Table 12: Buffers recipe for IMAC small screenings. ................................................... 33 
Table 13: Buffers recipe for IMAC 0.5-1L purification assays. .................................... 33 
Table 14: Buffers recipes for IEX chromatography. ...................................................... 36 
Table 15: Studied culture conditions for soluble expression of FH8BMP-2. ................ 41 
Table 16: Recipe of buffers of HIC purification step of recombinant FH8BMP-2 protein 
in E. coli M15/pQE-30. .................................................................................................. 45 
Table 17: Induction conditions of screening tests for soluble expression of recombinante 
FH8BMP-2. .................................................................................................................... 54 
Table 18: Recipe of buffers used in IMAC-Ni purification step of recombinant 
FH8BMP-2 protein in E. coli BL21 Ril/pETM. ............................................................. 57 
Table 19: Recipe of buffers used in first HIC purification step of recombinant 
FH8BMP-2 protein in E. coli BL21 Ril/pETM. ............................................................. 58 
Table 20: Washing buffers tested in HIC purification. .................................................. 62 
 
Table A1: Composition of solutions used in the project. ............................................... 77 
Table A2: List of enzymes that do not cut the bmp-2 fragment. .................................... 79 
 
 
 xiv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv 
 
Abbreviations 
 
APS – Ammonium Persulfate; 
BMP-2 – Bone Morphogenetic Protein 2; 
bp – base pair; 
BSA – Bovine Serum Albumin; 
CV – Column Volumes; 
Da  – Dalton; 
DNA – deoxyribonucleic acid; 
dNTPs – deoxyribonucleoside triphosphates; 
IPTG – Isopropyl β-D-1-thiogalactopyranoside; 
LB – Luria Broth; 
MCS – Multiple Cloning Site; 
min – minute(s); 
OD – optical density; 
PBS – Phosphate Buffer Saline; 
pI – isoelectric point; 
rpm –  revolutions per minute;  
RT – Room Temperature; 
SDS – sodium dodecyl sulfate; 
SDS-PAGE – Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis; 
TEMED – N,N,N’,N’-tetramethylethylenediamine; 
TGF-β – Transforming Growth Factor β; 
UV – Ultraviolet light. 
 xvi 
 
 
Motivation and aim of the project 
1 
 
Motivation and aim of the project 
 
The research on bone regeneration began decades ago with intensive studies on 
bone growth and healing. Most researches have been conducted to identify proteins 
capable to induce new bone formation and methods to perform biological applications 
that can lead to decrease or elimination of bone graft 
[1,2]
.  
It was in 1965 that a landmark on bone regeneration began with the work 
developed by Urist 
[3]
. The pioneering work of Urist showed that demineralized bone 
matrix had the capacity to induce endochondral bone formation and he named the 
mixture of proteins present in matrix as bone morphogenetic proteins (BMPs) 
[1,4]
. 
During the decade of 80s and 90s many investigators developed research in this area 
with the cloning of BMPs genes, demonstrating that these proteins are responsible to 
initiate a cascade of events, in which stem and mesenchymal cells are differentiated into 
osteogenic linage capable of producing bone tissue. Since then, several BMPs have 
been identified and purified from bone of different species, including human, for 
clinical applications 
[1,2,4]
.  
Bone morphogenetic protein 2 (BMP-2) is one of the main morphogenetic 
protein implicated in growth and regeneration of bone and cartilage 
[5,6]
. The expensive 
production of BMP-2 is a limitation of using this protein in therapeutic applications. A 
landmark step was made with the use of recombinant gene technology, which allowed 
the production of large quantities of recombinant human BMPs (rhBMPs) 
[7,8]
. Over the 
years has been reported the production of recombinant human bone morphogenetic 2 
(rhBMP-2) in prokaryotic system. However, to obtain BMP-2 protein in soluble form 
and in native conditions remains a challenge.  
 
In this work, the expression system chosen for the production of recombinant 
BMP-2 is the E. coli system and for soluble expression, the fusion protein technology 
with the novel FH8 tag is studied. Beyond the pQE-30 vector, it is used other two 
different vectors - pETM and pStaby1.2 - to express the fusion protein FH8BMP-2. The 
main purpose is to get an increase of soluble expression and purity level of target 
protein. The pET system is a powerful system for the cloning and expression of 
recombinant proteins in E. coli. In relation to pStaby1.2 system, the selection 
Motivation and aim of the project 
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mechanism is an important feature of this plasmid, because instead of antibiotics, this 
system uses antidote genes present naturally in plasmids. It is an advantage for 
commercialization systems, as it is described that contamination of the product by 
antibiotics is unacceptable by regulatory institutions.  
The main objectives of the project are the following: 
 Production of soluble recombinant BMP-2 protein fused to the 
FH8 tag, using the pQE-30 expression system; 
 Purification of the fusion protein via the FH8 tag by hydrophobic 
interaction chromatography and via affinity chromatography with nickel, using 
the His-tag in the system pQE-30; 
 Cloning of the gene coding for BMP-2 and its insertion into two 
other  expression systems (pETM and pStaby1.2) containing the His-FH8 tag; 
 Production of soluble recombinant fusion protein in both 
expression systems; 
 Purification of fusion proteins obtained in both systems (pETM 
and pStaby) by nickel affinity chromatography (His-tag) and hydrophobic 
interaction chromatography (FH8-tag);  
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Chapter 1: Review Literature 
 
1.1 Bone morphogenetic proteins 
 
Discovered in 1965, BMPs belong to a group of cytokines from the transforming 
growth factor-β (TGF-β) superfamily. To date, at least fifteen BMPs have been 
identified and characterized, and the members of BMPs family have been subdivide into 
subsets according to their amino acid sequence homology and similarity in protein 
structure. The main biological functions of BMPs are based especially on bone and 
cartilage formation 
[1,9]
. BMPs are homo or heterodimers, which chains are connected 
via disulphide bridges. In general, BMPs are biological active as both homo or 
heterodimer conformation. The structure of these proteins are based on conserved motif 
of seven cysteines, that are involved in the formation of six intrachain disulphide bonds 
and a single interchain bond, to promote the dimer formation 
[1,4,9]
. However, to form 
active dimer, BMP molecules are dissociated between the propeptide and mature region 
after proteolytical cleavage (Figure 1). These proteins are produced as large precursor 
molecules containing a hydrophobic signal sequence, a long and poorly conserved N-
terminal pro-region sequence, a mature domain with a highly conserved C-terminal 
region and an N-terminal region that varies among the different BMPs 
[1,9]
. The 
molecular signalling of BMPs is based on binding of these proteins to serine-threonine 
kinase receptors, which are present in the cells surface. This binding promotes 
important intracellular events that are responsible for activation of gene transcription, 
leading to cell proliferation and differentiation.  
In particular, there are three types of receptors for TGF-β superfamily members, 
but only receptors type I and II are involved in the signalling of BMPs. That is, the 
cascade of intracellular events that are involved with BMPs signalling occurs when the 
binding of these proteins to type I and II receptors (BMPRI, BMPRII) triggers a signal 
transduction cascade via Smad family proteins. As a consequence, BMP-Smad pathway 
will activate direct or indirectly target genes, responsible for osteoblast differentiation 
(Figure 2) 
[1,4,10]
.  
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Figure 1: Activation of BMP dimer. Adapted from [
9
] 
 
 
Figure 2: Gene transcription by BMP-Smad activation. Adapted from [
4
] 
 
1.1.1 Bone morphogenetic protein 2 (BMP-2) 
 
BMP-2 is one of the main BMPs member implicated in growth and regeneration 
of bone and cartilage, and therefore is one of the most intensely investigated growth 
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factor. BMP-2 is localized in bone tissue and is released in response to bone damage, 
stimulating differentiation of mesenchymal cells into osteoblasts and inducing cell 
proliferation via the Smad pathway demonstrated in Figure 2. In terms of structure, 
human BMP-2 consists of a long precursor protein of 396 amino acids, which is 
glycosylated, proteolytically cleaved and dimerized to form the mature homodimeric 
protein consisting of two 114 residue subunits 
[11]
. Other feature related to the structure 
of BMP-2 is a heparin-binding domain located in the N-terminal region of the mature 
polypeptide, which can cause alterations on its biological activity 
[1]
. The surface of the 
BMP-2 dimer is very hydrophobic causing its low solubility in aqueous solutions. Its 
osteoinduction properties have been subject of numerous preclinical and clinical 
experiments, described in literature (McKay and Sandhu (2002,2007); Govender et al. 
(2002); Raiche and Puleo (2004)), showing various therapeutic applications of BMP-2 
[2,5,12–15]
.  
1.2 Commercial BMP2 
 
 As a result of its therapeutic potential, BMP-2 has been studied as an alternative 
to autologous bone grafting in many clinical situations. These include spinal fusion, 
osteoporosis, treatment of bone defects, non-union fractures and root canal surgery 
[1,2,16–18]
. The approval commercial systems involving this protein in human application 
occurred in 2002, when the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMEA) have approved the clinical use of BMP-2. Currently, BMP-
2 is commercially available under the implant kit name Inductos™ (Medtronic Sofamor 
Danek and Wyeth Pharmaceuticals). This kit contains the BMP-2 protein as a 
lyophilized powder, dissolved in sterile water and is applied to an absorbable collagen 
matrix made of type 1 bovine collagen, for the treatment of acute open tibial fracture. 
Another similar product is the Infuse™ bone graft (Medtronic Sofamor Danek), 
indicated to the treatment of degenerative lumbar disc disease 
[2,5,12–15]
. These 
commercial preparations of BMP-2 are, however, produced abroad and are expensive 
[1,2,5]
.  
To overcome this bottleneck, during the last years, the investigation has been 
focused in strategies to increase production of BMP-2 at lower cost taking advantage of 
the advances in recombinant technology. 
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1.3 Recombinant production of BMP-2 
 
As with the majority of BMPs, reduced yields are obtained when native BMP-2 
is isolated from bone (around 1-2 µg/kg bone). Since the production and purification of 
this native protein presents difficulties and its clinical applications are limited by the 
potential health risks associated with its isolation from allogeneic bone donor, 
researchers have been encouraged to express BMP-2 protein, as well as the other BMPs 
by DNA recombinant technology 
[1,4,5,19,20]
.  
 
Recombinant human BMP-2 (rhBMP-2) was first obtained using mammalian 
cultures of chinese hamster ovary cells and the recombinant protein promoted ectopic 
bone and cartilage formation after two weeks of implantation in rats. After this 
pioneering work, other investigations were performed, to obtain rhBMP-2 using 
different expression systems (Table 1) 
[1,2,4]
. 
 
 
Table 1: Selected works reporting the production of rhBMP-2 in different expression systems. Adapted 
from 
[1]
 
BMP 
 
Expression system 
 
Novelty 
 
References 
 
BMP-2 CHO cells 
Bone formation and 
characterisation of 
expressed BMP-2 
Wang et al – 1990 
Israel et al  - 1992 
BMP-2 Insect cells 
Alternative expression 
system 
Maruoka et al – 1995 
BMP-2 E.coli 
The heparin binding 
domain reduces ALP and 
specific in vitro 
biological activity 
Ruppert et al  - 1996 
BMP-2 E.coli 
High density expression 
in bacteria 
Li et al  - 1998 
BMP-2 E.coli, pCYTEXP3 
Optimisation of 
refolding conditions 
Vallejo et al – 2002 
Vallejo and Rinas - 
2004 
BMP-2 E.coli 
Additional heparin 
binding domains 
enhance in vivo bone 
formation 
Wurzler et al - 2004 
BMP-2 E.coli, pET-11a 
Comparison with BMP-2 
propeptide 
Hillger et al - 2205 
BMP-2 E.coli, pET-21a 
Use of different 
refolding buffers 
Long et al – 2006 
BMP-2 E.coli, pET-25b 
Bioactivity in human 
stem cells 
Bessa et al - 2008 
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Nowadays, recombinant human BMPs (rhBMPs) are produced mainly by two 
expression systems: in mammalian cells or in bacteria. However, with mammalian cells 
expensive cultivation and poor yields render this procedure cost-intensive, especially at 
the industrial scale. Production in prokaryotic hosts is usually the preferred method, 
because these offer important advantages, such as, high yield, low cost 
cultivation/production and high bio-safety. One of prokaryotic systems widely used for 
the rapid and economical production of recombinant proteins is Escherichia coli (E. 
coli) 
[1,12,16,17,19]
.  
1.3.1 E. coli as a host 
 
Recombinant protein expression has revolutionized all aspects of the biological 
sciences, namely by the dramatically expansion of the number of proteins that can be 
studied both biochemically and structurally. In spite of the development of multiple 
nonbacterial recombinant expression systems over the last three decades (yeast, 
baculovirus, mammalian cell, cell free systems), E. coli is still the preferred host for 
recombinant protein expression, being widely used in industry and in academic research 
for this purpose 
[21–24]
. The vast advantages of E. coli turn it into a valuable organism for 
the high-level production of recombinant proteins. Among the important features, one 
can find: rapid growth, and expression, its well-characterized genetics, high product 
yields, easy of genetically manipulation, and it is relatively inexpensive to culture. The 
ability of this bacterial host to accumulate recombinant proteins up to 80% of its dry 
weight and to survive a variety of environmental conditions represent also important 
advantages for a wide range of downstream applications . Actually, the expression of 
human proteins in E. coli can reach a high success rate of 75% 
[21,22,24–26]
.  
However, common drawbacks can occur when using E. coli as an expression 
host. E. coli is not capable of producing eukaryotic post-translational modifications, 
such as glycosylation, which can be critical for the production of folded and active 
protein. Equally important is the fact that many proteins of biomedical interest have 
proved difficult to express properly in this host system because they are easily turned 
into insoluble and instable protein aggregates, identified as inclusion bodies. This 
aggregation of recombinant proteins in bacterial cells is a result of accumulation of high 
concentrations of folding intermediates or from inefficient processing by molecular 
chaperones 
[24,27]
. The main disadvantages of obtaining proteins from inclusion bodies 
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are related with solubilisation and refolding time-consuming steps and with the use of 
denaturing agents to extract protein of interest. This can cause problems with protein 
native conformation and consequently its activity. In the case of BMP-2, it is a protein 
that is biologically active in homodimeric form, so refolding steps are necessary after 
recovery from inclusion bodies 
[5,18,27]
. 
During the last years some investigators have performed important scientific 
work in this field (in Table 2 is possible to observe some of these publications) in order 
to produce and purify rhBMP-2 in E. coli, from the recovery of inclusion bodies.  
 
To overcome limitations associated to the production of recombinant protein in 
the form of inclusions bodies, several strategies have been described in literature to 
achieve soluble protein expression in E. coli. In following section it will be described 
some of these strategies, in which fusion expression technology has an important focus 
[23,28–30]
.  
 
Table 2: Studies of the production and purification of rhBMP-2 in E.coli. 
Author/date 
Study 
Zhang et al. / 
2011 
Expression, purification, and refolding of a 
recombinant rhBMP-2 
Zhang et al. / 
2010 
Optimized procedure for expression and renaturation 
of rhBMP-2 at high protein concentrations 
Sharapova et al. 
/2011 
Production of the rhBMP-2 in E. coli and Testing of 
Its Biological Activity in vitro and in vivo 
Bessa et al. / 
2007 
Osteoinduction in human fat-derived stem cells by 
rhBMP-2 produced in E. coli 
Long et al. / 
2006 
Expression, purification, and renaturation of rhBMP-2  
from E. coli 
 
1.4 Production of soluble recombinant BMP-2 
 
According to recent studies of structural genomics centres, more than half of all 
recombinant proteins accumulate in the form of insoluble aggregates when they are 
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overproduced in E. coli. However, in many biomedical applications, the objective is to 
obtain a product that is soluble, folded and active 
[21,31]
.  
Many methodologies that have been applied to increase the solubility of 
recombinant proteins in E. coli consist on the  manipulation of culture conditions, and 
altering the temperature at which the target protein is being produced 
[31,32]
. Also, 
changes in the E. coli expression strains, the use of different promoters and co-
expression methodology may contribute to improve the solubility of recombinant 
proteins in E. coli.  
In relation to BMP-2, there is only a study by Ihm et al in which is reported the 
soluble expression of BMP-2 in E. coli, using co-expression of thioredoxin gene in a 
different expression vector 
[18]
. 
As referred above, in most cases, strategies previously described do not solve 
completely the problem and other technologies are been widely explored as, for 
instance, the use of solubility fusion tags 
[31,32]
.  
1.4.1 Fusion Protein Technology  
 
Fusion protein technology is widely used for a rapid, efficient and cost-effective 
protein expression and purification process 
[33]
. Fusion tags are described to be proteins 
or peptides that are fused to the protein of interest and the main functions of these 
partners are to increase target protein production yields, promote its solubility and help 
on its purification 
[29,31,32]
. Over the years several fusion partners had already been 
described in literature (Table 3), but none of them is ideal with respect to all parameters 
referred above.  
Generally, it is difficult to choose the best fusion system for a specific protein of 
interest, due to different factors such as the expression system, the target protein itself 
(its stability or hydrophobicity) and the application of the purified protein. Thus, to 
determine the “best” tag for a specific target protein remains a challenging.  
Additionally, there are some factors related to the fusion tags that can affect the 
soluble protein expression levels and its purification, for example the placement of the 
tag, either in N-terminal or C-terminal. On the other hand, as many of affinity tags are 
large proteins, they can affect important characteristics like the structure of the protein 
to be studied. Also, biological activity of the recombinant expressed protein can be 
affected by the presence of a fusion tag and thus, in these cases, it is necessary to 
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remove the tag after the purification of the fusion protein 
[21,31,32,34]
. The most 
commonly used solution to remove the tag is to place a protease cleavage site between 
the solubility tag and the partner protein, allowing  an in vitro reaction after purification 
to remove the fusion tag 
[32]
. The commonly proteases used are: enterokinase, tobacco 
etch virus (TEV), thrombin, and factor Xa. The recovery process of target protein 
depends on the cleavage efficiency 
[35]
. 
Table 3: Commonly used solubility fusion tags. Adapted from [
32
] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1.1 Fusion system – FH8 tag  
 
The Hitag® fusion system consists of two novel fusion tags, the H and FH8 tags, 
which have demonstrated to increase protein expression levels in E. coli 
[36,37]
.  
The FH8 tag is an 8 kDa protein with 69 aminoacids and it is a homologous 
antigen secreted by the parasite Fasciola hepatica in the early stages of infection. 
Previous studies demonstrated that FH8 is a binding calcium protein by the presence of 
two EF-hands, which contain motifs involved in calcium coordination. Structurally, EF-
hands proteins are organized in functional domains which form stable helical bundles. 
The binding calcium properties of FH8 can cause conformational changes on its 
structure: when calcium binds to EF-hands domains, a switch from a closed to an open 
Tag 
 
Protein name 
 
Source organism 
 
MBP Maltose-binding protein E. coli 
GST Glutathione-S-transferase Schistosoma 
japonicum 
Trx Thioredoxin E. coli 
NusA Utilization substance E. coli 
SUMO Small ubiquitin-modifier Homo sapiens 
SET Solubility-enhancing tag Synthetic 
DsbC Disulfide bond C E. coli 
Skp Seventeen kilodalton protein E. coli 
T7PK Phage T7 protein kinase Bacteriophage T7 
GB1 Protein G B1 domain Streptococcus sp 
ZZ Protein A IgG ZZ repeat 
domain 
Staphylococcus 
aureus 
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conformation occurs. This reorientation of the protein conformation leads to the 
exposure of hydrophobic regions, which act as a target binding surface 
[36,38]
. Figure 3 
shows in detail this change of conformation after calcium binding (Figure 3 a)) and also 
the conformational change of hydrophobic area of FH8, which becomes larger in 
calcium loaded state (Figure 3 b)).   
As other members of the EF-hand family, FH8 tag demonstrates an unusual 
stability at high temperatures, and in the presence of calcium it is even more stable in 
other denaturant conditions, such as in the presence of high urea concentrations 
[38,39]
. 
Another interesting feature as a result of calcium interaction is a dimmerization 
of FH8 protein 
[38,39]
. A study conducted of FH8 shows the analysis, in non-denaturing 
conditions, of higher molecular weight band, suggesting the formation of dimers and 
pentamers. The pentamers are considered the most stable structure of the antigen and its 
formation is dependent on calcium 
[38]
. 
Currently, FH8 tag has been tested as solubility and purification tag with 
proteins difficult to express in E. coli 
[29,37,39,40]
. The fusion of these proteins to the FH8 
tag resulted in an increase of soluble expression and due to this positive effect, it will be 
studied the FH8 tag application with BMP-2 protein. 
 
Figure 3: a) Model structure of FH8 in the closed conformation (yellow). After calcium ligation occur a 
change to open conformation (green) and on the right is possible to see in detail the calcium binding 
loops, where calcium ions are represented by grey spheres. b) Molecular surface representation of FH8 in 
closed (left) and open (right) conformations. Adapted from [
38
] 
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Chapter 2: Materials and Methods 
2.1 Sterilization of material, culture media and solutions 
 
The sterilization of materials, solutions and culture media was carried out by 
autoclaving at 121°C for 20 minutes. Thermolabile solutions were sterilized by filtration 
with sterile filters of 0.2 micrometers. 
 
2.2 Chemical products, solutions and reagentes 
 
Composition of all solutions, loading samples and reagents used in this work are 
described in Table A1 of appendix 1. 
 
2.3 Vectors and Bacterial strains 
 
The plasmid vectors and the corresponding E. coli strains used to produce the 
recombinant fusion protein in this study are presented in Table 4. It is important to note 
that only the construction of pQE-30/FH8BMP-2 was already available. The other two 
constructions were conducted in the scope of this work. A more detailed description of 
each plasmid vector will be presented in this section. 
Table 4: Plasmid vectors and bacterial strains used in the present work. 
Backbone plasmid  Constructed plasmid E.coli strain Phenotype 
pQE-30 (QIAexpress 
system – Quiagen) 
 pQE-30/FH8BMP2 M15[pREP4] 
NaIS, StrS, RifS, Thi–, 
Lac–, Ara+, Gal+, Mtl–
, F–, RecA+, Uvr+, 
Lon+ 
pETM (EMBL)  pETM/FH8BMP2 
BL21 CodonPlusRil 
B F–ompT hsdS(rB– 
mB–) dcm+ Tetr gal 
endA Hte [argU ileY 
leuWCamr] 
Rosetta 2 
F–ompT hsdSB(rB
–mB–
) gal dcm pRARE23 
(CamR) 
pStaby1.2 
(StabyExpress system 
- Delphi) 
 pStaby1.2 /FH8BMP2 SE1 
gal, dcm, DE3 (lacI, T7 
polymerase under the 
control of the lacUV5 
promotor), ccdB+ 
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2.3.1 pQE-30 QIAexpress system 
 
This expression system, distributed by Qiagen, consists of pQE-30 vector and it 
was used to express BMP-2 protein with and without the FH8 fusion tag. The pQE-30 
plasmid, represented in Figure 4, uses a transcription–translation system based in T5 
promoter/lac operator, which allows high expression levels of recombinant proteins in 
E. coli 
[41]
. This system has other important feature: the presence of a 6xHis-tag 
codifying sequence in the N-terminal, which when genetically bound to the protein of 
interest, can facilitate the purification process by affinity chromatography.  
 
 
Figure 4: Graphic of plasmid map of pQE-30, Qiagen. Adapted from 
[41] 
 
2.3.2 pETM vector 
 
The pETM vectors derive from the pET vector series initially developed by 
Studier and colleagues, which represent nowadays a powerful system to cloning and 
expression of recombinant proteins in the E. coli host. The pETM plasmids use the 
same transcription-translation system as the pET collection based in T7 promoter to 
clone the genes of interest. Some important features of pETM vectors are: the presence 
  Materials and Methods 
15 
 
of two 6xHis-tags (one before and other after the MCS), a conserved multiple cloning 
site (MCS) and a TEV protease recognition site. 
In this particular study it was used the pETMFH8 plasmid, containing the FH8 
tag and a TEV recognition site between the fusion tag and protein. This expression 
vector has also the presence of a gene responsible to confer kanamycin resistance. The 
MCS is located between TEV site and the second 6xHis-tags. A schematic diagram of 
pETMFH8 vector is shown in Figure 5. 
 
 
Figure 5: Graphic of plasmid map of pETMFH8, EMBL. 
 
2.3.3 pStaby1.2 Express System 
 
This expression system, commercialized by Delphi Genetics, was also used to 
clone bmp-2 gene and produce FH8BMP-2 protein. The plasmid used in this work was 
the pStaby1.2FH8, which has the following features: T7 promoter, 6xHis-tag at the C-
terminal end of the protein; the plasmid is stable without the use of antibiotics. As in the 
case of pETMFH8 vector, the gene of codifying for BMP-2 was cloned into the 
pStaby1.2FH8 plasmid, but in this vector FH8 tag and the 6xHis residues are in 
opposite ends, which may improve the purification process. Plasmid scheme of 
pStaby1.2FH8 is displayed in Figure 6.  
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Figure 6: Graphic of plasmid map of pStaby1.2FH8, Delphi. 
 
2.4 Molecular Biological Methods 
2.4.1 Extraction of plasmid DNA and template sequence of BMP-2 from E. coli 
 
The pQE-30/BMP-2 plasmid, already available in the lab, was used as a 
template for amplifying the codifying sequence of bmp-2 gene. E. coli M15 pQE-
30/BMP-2 cells were incubated at 37 ºC o/n from a plate containing 
LB/amplicillin/kanamycin and plasmid DNA was extracted. The DNA from bacterial 
cultures containing the pETMFH8 (LB/kanamycin) and pStaby1.2FH8 (LB/ amplicillin) 
plasmids were prepared in the same way. The DNA extraction was performed using the 
NZYMiniprep (Nzytech) kit, according to manufacturer’s instructions [42]. At the end of 
the protocol, fractions of 30-50 µl were recovered, containing DNA of template 
sequence and plasmid DNA. 
 
2.4.2 PCR of insert fragment – bmp-2 gene 
 
To obtain the desired constructs, the bmp-2 gene was amplified by PCR using 
specific primers accordingly to the destination vector (pETMFH8 or pStaby1.2FH8). 
The first step before proceeding to the amplification reaction was primer design, in 
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which specific pairs of primers were constructed, each pair related to the corresponding 
vector. Template sequence was amplified using the primers presented in Table 5. 
 
Table 5: Sequence of primers used in PCR reaction. 
Cloning bmp-2 
gene into 
Primer forward – 5’- 3’ Primer reverse – 5’- 3’ 
pETMFH8 TCTATTCCATGGGATCCACTTTCGGCCACGA
TGGTAAAGG 
AATAGACTCGAGCTAGCGACA
GCCACAACCCTCCACAAC 
pStaby1.2FH8 TCTATTGAGCTCGAGAATCTTTATTTTCAGG
GCATGACTTTCGGCCACGATGGTAAAG 
AATAGACTCGAGGTAGCGACA
GCCACAACCCTCCACAAC 
 
The forward primers contain the recognition sequences (nucleotides underlined) 
for NcoI and SacI to be used in the pETMFH8 and pStaby1.2FH8 plasmids, 
respectively; the reverse primers contain the same restriction site for XhoI.  
PCR was performed in 50 µl of reaction mixture containing 1 µl of DNA 
template, 1 µl of each primer, 1 µl of dNTP’s mixture, 10 µl 5x Phusion HF buffer, 0.5 
µl of Phusion DNA Polymerase (Fermentas) and ultrapure water to complete final 
volume. The amplification reaction was held on a thermal cycler My CyclerTM Thermal 
Cycler (Biorad) with program described in Table 6. 
After visualization on agarose gel, the two products of amplification (bmp-2 for 
pETMFH8 and bmp-2 for pStaby1.2FH8) were purified to be further cloned into the 
final vectors. 
 
 
Table 6: PCR program. 
 Step Temperatute, Time Cycles 
 Initial Denaturation 98 ºC, 30 seconds 1 
 Denaturation  98 ºC, 10 seconds 
30-35  Annealing 68 ºC, 30 seconds 
 Elongation 72 ºC, 30 seconds 
 Final extension 72 ºC, 10 minutes 1 
 Soak 4 ºC, ∞ 1 
 
  Materials and Methods 
18 
 
2.4.3 Agarose Gel Electrophoresis 
 
For DNA analysis, electrophoresis procedure was performed using agarose gel 
stained with GreenSafe Premium (Nzytech). GreenSafe Premium is a new nucleic acid 
stain which can be used as a safer alternative to the traditional ethidium bromide stain 
for detecting nucleic acids in agarose gels 
[43]
. The agarose was dissolved in TAE buffer 
and the percentages of agarose gels varied between 1% and 1.2 %, according to DNA 
fragment that is visualized. The DNA samples were mixed with 5x sample loading dye 
and then were loaded into the gel. The DNA molecular weight used in this project was 
NZYDNA Ladder III (Nzytech). Electrophoresis running occurred at 90 V in horizontal 
cells (Biorad) with TAE buffer. The gels photos were taken by a transilluminator Gel 
Doc 2000 (BioRad). 
2.4.4 DNA purification 
 
After 1% agarose gel electrophoresis (technique described in section 2.4.3), the 
DNA bands of PCR products were cut off using UV light panel of a transilluminator 
Gel Doc 2000 (BioRad) and were treated following standard protocol of QIAEX II Gel 
Extraction Kit (QIAGEN) 
[44]
. 
2.4.5 Digestion of DNA with restriction enzymes 
 
For the digestion of DNA fragments, 2 µg of DNA was mixed with 
corresponding enzymes in a reaction volume of 50 µl, in the presence of the 
recommended 10x reaction buffer and BSA 100x solution. The reaction mix was 
incubated at 37 ºC o/n and stopped by incubation at 65ºC for 20 min. The incubation 
time of reaction mix and concentration of restriction endonuclease were applied 
according to manufacturer’s instructions. Description of restriction enzymes used 
during this procedure is presented in Table 7.  
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Table 7: Description of restriction enzymes used. 
 Restriction Enzyme Cleavage site  Source 
 NcoI 
 
5'-C^C A T G G-3' 
3'-G G T A C^C -5' 
 New England Biolabs 
 SacI 
 
5'-G A G C T^C-3' 
3'-C^T C G A G-5' 
 New England Biolabs 
 XhoI 
 
5'-C^T C G A G-3' 
3'-G A G C T^C -5' 
 New England Biolabs 
 
2.4.6 Dephosphorylation of Plasmid DNA 
 
Dephosphorylation of cloning vectors pETMFH8 and pStaby1.2FH8 was carried 
out with Shrimp Alkaline Phosphatase (SAP) of Fermentas. This enzyme is used to 
prevent re-circularization and re-ligation of linearized vector DNA. Dephosphorylation 
procedure was performed in 55 µl of reaction mixture, containing linear DNA, 5.5 µl of 
10x reaction buffer, 1 µl of SAP and ultrapure water to complete final volume. The 
mixture was incubated at 37 ºC, during 1 h and stopped at by incubated at 65ºC for 15 
min. After SAP inactivation, plasmid DNA was purified according to the procedure 
described in section 2.4.4. 
 
2.4.7 DNA quantification 
 
The concentration of nucleic acids was measured by spectrophotometry with 
NanoDrop™ 1000 (Thermo Scientific), in which 2 µl of DNA sample was used.  
 
2.4.8 Ligation of DNA insert fragment to the vector 
 
After purification of the insert and vector DNAs, it was estimated the amount of 
insert required at a specific molar ratio of vector:insert for DNA ligation. In this work, 
for ligation between insert fragment bmp-2 and pETMFH8 (ligation a) a molar ratio of 
vector:insert of 1:3 was used; the ligation between insert fragment bmp-2 and 
pStaby1.2FH8 (ligation b) involved a molar ratio of vector:insert of 1:2. Apart from 
insert fragment and vector, ligation reactions implicated the mixture of T4 DNA Ligase 
(Promega) and the recommended buffer. In this way, ligation reactions of 10 µl and 20 
µl to ligation a and b, respectively, were prepared. To ligation a, it was mixed 2 µl of 
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vector DNA, 2.4 µl of insert DNA, 1 µl of 10x ligase buffer, 0.5 µl of T4 DNA ligase 
3u/µl and ultrapure water to complete final volume. Reaction mixture of ligation b 
containing 15 µl of DNA vector, 0.5 µl of insert DNA, 2 µl of 10x ligase buffer, 1 µl of 
T4 DNA ligase 3u/µl (Promega) and ultrapure water up to final volume. Both reactions 
were incubated o/n at 4 ºC.  
E. coli DH5α and Top 10 cells were transformed with the resulting DNA from 
ligation of bmp-2 insert and the corresponding plasmids (methodology described in 
section 2.4.10). 
  
2.4.9 Preparation of chemical competent E. coli cells 
 
A pre culture of 10 ml of E. coli DH5α or Top 10 cells was prepared and 
incubated at 37 ºC with shaking o/n. Then 5 ml of pre culture was added to 250 ml LB 
medium with the corresponding antibiotics and cells grew at 37 ºC with vigorous 
shaking (200-250 rpm) until OD600 reaches 0.5. The culture was kept on ice for 10 min 
and then transferred to sterilized 50 ml falcon tubes, followed by a centrifugation at 
4000 g (4 ºC) for 10 min. For each falcon tube, the pellet was resuspended carefully in 
20 ml of ice-cold TB solution and kept on ice for another 10 min. Then, the suspension 
cells were recovered by centrifugation at 4000 g (4 ºC) for 10 min and the pellet was 
resuspended in equivalent volume of TB solution and DMSO was added for each tube 
to a final concentration of 7%. The competent cell suspension was dispensed into 
microtubes (200 µl/tube) and stored at -80 ºC. 
 
2.4.10 Transformation of recombinant DNA to competent E. coli cells 
2.4.10.1 Transformation of chemically competent DH5α E. coli cells 
 
This protocol was made to transform DNA of ligation a, according to the 
following steps: 8 µl of DNA solution were added to 50 µl aliquot of DH5α competent 
cell suspension and this mixture was incubated on ice for 20 min. A heat-shock was 
made at 42 ºC for 45 seconds and after cell suspension was kept on ice for 2 min. Then, 
800 µl of LB medium was added and the mixture was continually incubated at 37 ºC for 
1h. At the end, transformed cell suspension was plated onto LB/kanamycin plate. 
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Separately and following the same procedure, it was prepared a DH5α cells control 
(without ligation reaction) and a negative control (ligation without insert fragment). The 
plates were incubated at 37 ºC overnight to develop colonies of the transformed cells. 
 
 2.4.10.2 Transformation of chemically competent Top 10 E. coli cells 
 
To transform DNA of ligation b it was performed a similar transformation 
protocol to the previous one, but in this case using competent Top 10 E. coli cells. In 
this way, 20 µl of DNA solution were added to 200 µl aliquot of Top 10 competent cell 
suspension and this mixture was incubated on ice for 30 min. A heat-shock was made at 
42 ºC for 30 seconds and after cell suspension was kept on ice for 10 min. Then, 800 µl 
of SOC medium was added and the mixture was continually incubated at 37 ºC for 1h. 
At the end, transformed cell suspension was plated onto LB/ ampicillin plate. Separately 
and following the same procedure, it was prepared a Top 10 cells control (without 
ligation reaction) and a negative control (ligation without insert fragment). The plates 
were incubated at 37 ℃ overnight to develop colonies of the transformed cells. 
 
2.4.11 Screening of Transformants 
 
To determine if the insert fragment of bmp-2 gene was successfully cloned into 
pETMFH8 and pStaby1.2FH8 vectors, colony PCR methodology was used for 
screening the transformed bacteria. Colony PCR protocol is presented as follows:  about 
half of a isolated colony (from transformed cells plate) was picked using a sterile 
toothpick and resuspended in a 25 µl amplification reaction, which containing 1 µl of 
MgCl2 2 mM, 0.5 µl of dNTP’s mixture, 0.5 µl of T7 forward primer, 0.5 µl of T7 
reverse primer, 2.5 µl of 10x reaction buffer, 0.5 µl of DNA Taq polymerase 5 u/µl 
(Nzytech) and ultrapure water up to the final volume. Target DNA was amplified using 
cycling conditions appropriate for screening primers used (universal T7 forward and T7 
reverse primers) and size of amplifier product. The amplification reaction was held on a 
thermal cycler My CyclerTM Thermal Cycler (Biorad) with program described in Table 
8. An aliquot of the completed PCR was recovered and analysed by agarose gel 
electrophoresis to identify the product length, which indicates if the correct insert is 
present in the clone. 
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Table 8: Colony PCR program. 
 
 
 
 
 
 
2.4.12 DNA Sequencing 
 
All constructions made with bmp-2 insertion in pETMFH8 and pStaby1.2FH8 
vectors were confirmed by sequencing using the Eurofins MWG Operon (Germany) 
service. 
 
2.4.13 Transformation of chemically competent BL21 Codon Plus Ril and 
Rosetta 2 E. coli cells 
 
The general protocol followed in this transformation step was the same to the 
described in section 2.4.10.1. 
 
2.4.14 Transformation of chemically competent SE1 E. coli cells 
 
The general protocol followed in this transformation step was the same to the 
described in section 2.4.10.1. 
 
2.5 Soluble Expression of recombinant FH8BMP-2 protein in E. coli 
 
This section will describe the main stages of cell growth, protein induction and 
recovery of soluble fraction of target protein, FH8BMP2, for the different E. coli strains 
used in this work. 
 Step Temperatute, Time Cycles 
 Initial Denaturation 94 ºC, 7 minutes 1 
 Denaturation 94 ºC, 30 seconds 
30  Annealing 55 ºC, 30 seconds 
 Elongation 72 ºC, 2 minutes 
 Final extension 72 ºC, 10 minutes 1 
 Soak 4 ºC, ∞ 1 
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2.5.1 Study of the soluble expression conditions of recombinant FH8BMP-2 
protein in E. coli M15/pQE-30 
 
These experiments were carried out to evaluate the effect of culture conditions 
for soluble expression of FH8BMP-2 protein produced in E. coli M15/pQE-30. 
From a freshly bacterial biomass of E. coli M15[pREP4] pQE-30/FH8BMP-2, a 
pre culture of  25 ml LB/ampicilin/kanamycin was prepared and it was allowed to grow 
at 37 ºC, o/n with shaking (200 rpm). The next day, four erlenmeyer flasks were 
prepared as follows: in each one, containing 250 ml LB/amplicilin/kanamycin medium, 
was inoculated 1/50 ratio of the pre culture. Cell cultures were incubated at 37 ºC and 
200-250 rpm until the OD600 reach a value between 0.4-0.6. At this point, the expression 
of FH8BMP-2 was induced by the addition of IPTG to a final concentration of 0.1 mM 
and incubated at 18-20 ºC at two different induction times: two erlenmeyer flasks were 
incubated for 16h and the other two were induced for 24h. At the end of induction 
times, cells were harvested by centrifugation at 4000 g (4 ºC) for 20 min and the 
resulting cell pellets were stored at -20 ºC.  
To study the optimal conditions of soluble expression of FH8BMP-2, cell pellets 
were resuspended in two different lysis buffers: Buffer A – 50 mM Tris-HCl, 250 mM 
NaCl, pH 8 and Buffer B – 50 mM Sodium Phosphate, 300 mM NaCl, pH 8. Thus, the 
four pellets obtained (each one corresponding to 250 ml of culture), were resuspended 
in 10 ml of buffer A and buffer B with 1 mM PMSF (phenylmethylsulfonyl fluoride 
(serine protease inhibitor)) as proteases inhibitor, according to their induction time 
culture, as shown in the scheme of Figure 7.  
 
 
Figure 7: Soluble expression conditions of FH8BMP-2 in pQE system. 
 
Then bacterial cells were incubated at room temperature for 15 min and then transferred 
to ice and further sonicated (Branson sonifier – 30 seconds on and 30 seconds off for 6 
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cycles, Duty cycle 50 % and Output control 5) and soluble fraction was separated from 
its insoluble part by centrifugation at 16000 g (4 ºC), for 30 min. Samples of soluble 
fractions and total lysates (the sample of total lysate corresponds to the total extract of 
E. coli immediately after cell lysis) of the four cultures studied were further analyzed by 
electrophoresis under denaturing conditions: SDS-PAGE (methodology described in 
section 2.6). 
 
2.5.2 Soluble expression of recombinant FH8BMP-2 protein in E.coli M15 
/pQE30 
 
After being determined the conditions that maximize the soluble production of 
recombinant FH8BMP-2, its expression was performed through total cultures of 1L 
resulting from small cultures of 250 ml. The soluble production of target protein was 
made according to the process described in section 2.5.1. 
 
2.5.3 Study of the soluble expression conditions of recombinant FH8BMP-2 
protein in pETM: E. coli BL21 Codon Plus Ril and Rosetta2  
 
In the extent of these experiments, two main goals were established: to 
determine the most favourable conditions of soluble expression of FH8BMP-2 in pETM 
system and to select the E. coli strain that maximize FH8BMP-2 production. To 
accomplish these goals, small scale screenings using cultures of 20 ml were performed. 
3 ml of LB medium and specific antibiotics (final concentrations of kanamycin: 50 
ug/ml and chloroamphenicol: 33 ug/ml) were added to 15 ml falcon tubes and single 
colonies were picked from corresponding bacterial biomass and inoculated in the 
medium.  Pre-cultures had grown at 37 ºC, o/n with shaking (200 rpm). The next day, 
20 ml LB/kanamycin/chloroamphenicol medium was inoculated with 1/50 ratio of the 
each pre culture (400 µl) using 100 ml erlenmeyer flasks. Cell cultures were incubated 
at 37 ºC and 200-250 rpm until the OD600 reach a value between 0.4-0.6 (2-3h of 
incubation). At this point, liquid cultures of 20 ml were divided into 2×10 ml cultures in 
50 ml falcons to study different inductor concentrations and time of induction. In this 
way, cultures were placed as follows: the first falcons (2× 50 mL falcons, corresponding 
to BL21 Codon Plus Ril and Rosetta2 cultures) at 18ºC, o/n with IPTG to a final 
concentration of 0.2 mM and the second group of falcons (2 × 50 mL falcons, 
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corresponding to BL21 Codon Plus Ril and Rosetta2 cultures) were incubated at 30ºC 
for 3h with IPTG 0.5 mM.  
After the induction period, cells were harvested by centrifugation at 4000 g, 4 
ºC, for 10 min and resulting cell pellets were stored at -20 ºC, o/n.  
The next day, bacterial pellets were resuspended in 5 ml of lysis buffer - 50 mM 
Tris-HCl, 250 mM NaCl, pH 7.4 with 1 mg/ml lysozyme and 1 mM of PMSF; 
incubated at room temperature for 10 min and then transferred to ice and sonicated 
(Branson sonifier – 30 seconds on and 30 seconds off for 6 cycles in position 8, Duty 
cycle 50 % and Output control 5). Soluble fraction was separated from its insoluble part 
by centrifugation at 16000 g (4 ºC), for 30 min. Aliquots of soluble fractions and total 
lysates of all cultures studied were further analyzed by electrophoresis under denaturing 
conditions: SDS-PAGE (methodology described in section 2.6). 
 
2.5.4 Soluble expression of recombinant FH8BMP-2 protein in E. coli BL21 Ril 
/pETM10 
 
After being determined the conditions that maximize the production of 
recombinant FH8BMP-2, its expression was performed through total cultures of 1L, as 
a result of four cultures of 250 ml. The soluble production of target protein was made 
according to the process described in section 2.5.3. 
 
2.5.5 Conditions study of soluble expression of recombinant FH8BMP-2 
protein in E. coli SE1/pStaby1.2  
 
The process followed to solubility analysis of FH8BMP-2 protein in pStaby1.2 
vector using SE1 E. coli strain was identical to that described in section 2.5.3, with the 
exception of certain aspects: it was studied another induction condition at 37 ºC for 3h 
and cultures were prepared without antibiotics due to the special feature of pStaby1.2 
system, described previously. 
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2.6 Electrophoresis under denaturing conditions: SDS-PAGE 
 
This methodology was used to analyze all the samples of protein extracts and 
fractions obtained before, during and after the purification process. This type of 
electrophoresis is based on Laemmli system 
[45]
. This system uses discontinuous 
polyacrylamide gel to separate proteins based on molecular weight; an electric field is 
applied across the gel, causing the negatively-charged proteins to migrate across the gel 
towards the positive electrode (anode). Depending on their size, each protein will move 
differently through the gel matrix: short proteins will more easily fit through the pores 
in the gel, while larger ones will have more difficulty. The polyacrylamide gel is cast as 
a separating gel (usually known as resolving or running gel) topped by a stacking gel 
and secured in an electrophoresis apparatus. In this system, denaturation of proteins 
occurs in the presence of β-mercaptoethanol to reduce disulﬁde bonds and SDS reagent, 
which confers negative charge to molecules making the running uniquely dependent on 
differences in molecular weight. Ammonium Persulfate (APS) and 
Tetramethylethylenediamine (TEMED) catalyze the polymerization of acrylamide 
solutions into gel matrices. SDS-PAGE gels composition is presented in Table 9. 
Table 9: SDS-PAGE gels composition. 
Reagents Resolving gel Stacking gel 
40% Acrilamid/Bis 3 ml 0.5 ml 
0.5M Tris-HCl, pH 6.8 - 1.25 ml 
0.5M Tris-HCl, pH 8.8 2.5 ml - 
10% SDS 100 µl 50 µl 
10% APS 50 µl 25.5 µl 
TEMED 5 µl 2.5 µl 
H2O 4.35 ml 3.17 ml 
Final volume 10 ml 5 ml 
 
Before application into the gel, samples were treated by adding 5x loading 
sample buffer and by incubating in a bath at 100 ºC for 5-10 min. If samples were not 
immediately loaded into the gel, they were kept on ice or at -20 ºC. The protein 
molecular weight marker used in SDS-PAGE electrophoresis was PageRuler™ 
Unstained Broad Range Protein Ladder (5-250 kDa) from Fermentas. 
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The electrophoresis run occurred in vertical units with 1x running buffer at 
constant voltage of 120 V, and at the end gels were stained by Coomassie Blue staining 
method described below. 
After gel running, the gel is placed in a box for the following washing steps: 
distillated water is added to the gel and heated in the microwave for 30 seconds; then 
the box with the gel is placed on a shaker for 3 min and this washing step is repeated 
twice with fresh distillated water. After washing steps, enough Coomassie Blue solution 
(its recipe is described in Table A1 of appendix 1) is added to cover the gel in the box 
and is heated in the microwave for 30 seconds and then the box with the gel is placed on 
a shaker for finishing the staining during 30 min. At the end, when staining solution is 
poured off, distilled water is added for destaining of the gel and then gel can be 
photographed or dried for long term storage. 
 
2.7 Purification of recombinant FH8BMP-2 protein  
 
Purification of soluble fraction of FH8BMP-2 was carried out by the 
performance of several experiments which embraced the following chromatographic 
techniques: hydrophobic interaction; immobilized metal ion affinity and ion exchange. 
The first two purification techniques were executed in small screenings and then in 
column system. Ion exchange chromatography was used as a second purification step in 
column system. 
2.7.1 Hydrophobic Interaction Chromatography (HIC) 
 
The FH8 tag was used as purification tag through the use of HIC technique to 
purify the fusion protein. HIC is a liquid chromatography technique, which separates 
biomolecules based on differences in their surface hydrophobicity. Therefore, 
hydrophobic amino acids exposed on proteins surface can interact with the hydrophobic 
surface of HIC medium and since the amount of exposed hydrophobic amino acids 
varies between proteins it is possible obtain their separation and the specificity of the 
process. 
HIC media contain ligands of alkyl or aryl groups coupled to an inert matrix of 
spherical particles. The porosity of matrix allows high internal surface area and the 
ligand plays an important role in the final hydrophobicity of HIC media. 
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Most HIC experiments are performed in four main stages: equilibration; sample 
application and wash; elution and regeneration. The first step is the equilibration of 
stationary phase, which is performed by adding salt to the mobile phase to get the 
desired start conditions: binding of interest protein in HIC protocol is promoted by 
moderately high salt concentrations. The second step corresponds to sample load onto 
the column and when sample loading is completed and the column has been washed so 
that all non-bound proteins have passed through, conditions are altered to begin elution. 
Proteins are released from the column by decreasing the salt concentration in the elution 
buffer. As the level of salt decreases, proteins with the lowest hydrophobicity begin to 
elute from the column. In the final step of regeneration, all molecules still attached to 
the column are removed. 
  
In this work, for the small-scale purification of FH8BMP-2 it was used a Phenyl 
Sepharose™ 6 Fast Flow (high substitution) resin (GE Healthcare). Phenyl Sepharose 6 
Fast Flow is composed of cross-linked 6% agarose beads modified with standard 
aromatic phenyl groups via uncharged, chemically-stable ether linkages. 
 In larger scale assays a prepacked 5 ml column Phenyl Sepharose™ 6 Fast Flow 
(high sub) (GE Healthcare) was used.  
Tables 10 and 11 present the description of all buffers used in HIC purification 
protocols performed in this study. The volumes used in each step of HIC experiments 
and protocols used in small and larger scale assays are described below.  
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Table 10: Buffers recipe for FH8-HIC small screenings. 
 
Table 11: Buffers recipe for FH8-HIC 0.5-1L purification assays. 
 
HIC - Small scale Screenings 
 
Incubation 
conditions 
Screening 
Target 
protein 
Lysis Buffer 
Binding 
Buffer 
Washing 
Buffer 
Elution 
Buffer 
Other 
additives 
Time ºC 
Screening  
1 
pQE-
30/FH8BMP-2 
50 mM Tris, 
250 mM NaCl, 
pH 8 
 
50 mM Tris, 
250 mM 
NaCl, pH 8 
 
50 mM Tris, 
250 mM NaCl, 
pH 8 (1:2) 
 
50 mM 
Tris, pH 10 
 
 3h 4/ 
RT 
Screening 
2 
pQE-
30/FH8BMP-2 
50 mM 
Naphosphate, 
300 mM NaCl, 
pH 8 
50 mM 
Naphosphate, 
300 mM 
NaCl, pH 8 
50 mM 
Naphosphate, 
300 mM NaCl, 
pH 8 (1:2) 
 
50 mM 
Tris, pH 10 
 
 3h 4/ 
RT 
Screening 
3 
pQE-
30/FH8BMP-2 
50 mM Tris, 
250 mM NaCl, 
pH 7 
50 mM Tris, 
250 mM 
NaCl, pH 7 
50 mM Tris, 
250 mM NaCl, 
pH 7 (1:2) 
 
50 mM 
Tris, pH 10 
 
5 mM 
of 
CaCl2 
1h RT 
Screening 
4 
pQE-
30/FH8BMP-2 
50 mM Tris, 
250 mM NaCl, 
pH 7.5 
50 mM Tris, 
250 mM 
NaCl, pH 7.5 
50 mM Tris, 
250 mM NaCl, 
pH 7.5 (1:2) 
50 mM 
Tris, pH 10 
 
5 mM 
of 
CaCl2 
1h RT 
HIC - 0.5-1L Purification Assays 
 
Purification 
assay 
Target protein Lysis Buffer 
Binding 
Buffer 
Washing Buffer* 
Elution 
Buffer 
Other 
additives 
Assay 1 pQE-
30/FH8BMP-2 
50 mM Tris, 250 
mM NaCl, pH 7 
50 mM Tris, 
250 mM 
NaCl, pH 7 
50 mM Tris, 250 
mM NaCl, pH 7 
(1:2) 
50 mM Tris, 
pH 10 
5 mM of 
CaCl2 
Assay 2 pQE-
30/FH8BMP-2 
50 mM 
Naphosphate, 300 
mM NaCl, pH 7 
50 mM 
Naphosphate, 
300 mM 
NaCl, pH 7 
50 mM 
Naphosphate, 300 
mM NaCl, pH 7 
(1:2) 
50 mM Tris, 
pH 10 
 
Assay 3 pETM/FH8BMP
-2 
50 mM Tris, 250 
mM NaCl, pH 7.4 
50 mM Tris, 
NaCl  250 
mM, pH 7.4 
W1 – 50 mM Tris, 
250 mM NaCl, pH 
7.4 (1:2); 
W2- dH2O 
50 mM Tris, 
pH 10 
5 mM of 
CaCl2 
Assay 4 pETM/FH8BMP
-2 
50 mM Tris, 250 
mM NaCl, pH 7.4 
50 mM Tris, 
250 mM 
NaCl, pH 7.4 
W1 – 50 mM Tris, 
250 mM NaCl, pH 7 
.4 (1:2); 
W2 – H2O; 
W3 – 50 mM Tris, 
250 mM NaCl, pH 
7.4 + 2.5 M MgCl2; 
W4 – 50 mM Tris, 
250 mM NaCl, pH 
7.4 + 1.5 M Urea + 
5% glycerol; 
 
50 mM Tris, 
pH 10 
5 mM 
CaCl2 
Assay 5 pETM/FH8BMP
-2 
50 mM Tris, 250 
mM NaCl, pH 7.4 
50 mM Tris, 
250 mM 
NaCl, pH 7.4 
50 mM Tris, 250 
mM NaCl, pH 7.4, 
3%(w/w) 
isopropanol 
50 mM Tris, 
pH 10, 
10%(w/w) 
isopropanol 
5 mM 
CaCl2 
 
*W1-W4: corresponds to the different washing buffers used during purification assays. 
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2.7.1.1 Small scale screenings protocol 
 
The procedure below has been used to purify the soluble fraction of FH8BMP-2 
in small amounts in order to determine the optimal conditions for HIC purification to 
subsequently perform larger scale purifications. The stages relative to the recovery of 
soluble fraction (ressuspension of cell pellet, enzymatic and mechanical cell lysis) are 
described in section 2.5.1 and 2.5.3. 
  
1. The first step in this small scale purification protocol was the preparation of 
resin: since it was used 15 ml tubes, the Phenyl Sepharose™ 6 Fast Flow resin 
was divided equally in these tubes (1-2 ml of resin solution in each tube). Then, 
each tube was centrifuged for 10 min at 4 ºC to 4000 g to remove the 70% 
ethanol which is stored with the resin; 
2. Resin was washed and equilibrated by adding 2 ml of the correspondent binding 
buffer and centrifuged for 10 min at 4 ºC to 4000 g; 
3. In screenings 3 and 4, calcium (CaCl2) at 5 mM of concentration was added to 
soluble fraction of FH8BMP-2 prior to sample incubation with the resin; 
4. 2.5-5 ml of soluble fraction of FH8BMP-2 was added to the resin and incubated 
at specific period of time and temperature – time and temperature of incubation 
(described in Table 10) were two variables to test in screening assays; 
5. At the end of incubation time, each tube was centrifuged for 10 min at 4 ºC to 
4000 g to collect the flowthrough sample and an aliquot of this sample was 
stored for SDS-PAGE; 
6. Resin was washed with 2 ml of correspondent washing buffer and centrifuged 
for 10 min at 4 ºC to 4000 g. Washing samples were collected and aliquoted to 
be analyzed by SDS-PAGE; 
7.  Finally target protein was eluted three times with 2 ml of correspondent elution 
buffer and centrifuged for 10 min at 4 ºC to 4000 g. Purified samples were 
collected and aliquoted to be analyzed by SDS-PAGE; 
8. After elution, impurities and proteins that remained attached to the resin were 
removed by adding urea at 8M concentration. Corresponding sample was 
collected and aliquoted to be analyzed by SDS-PAGE; 
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9. Resin was regenerated by washing it with distilled water and 20 % ethanol to be 
stored and then used for a new purification. 
 
2.7.1.2 0.5-1L Purification Assays protocol 
 
The protocol used in these purification assays applies for the HIC purification 
technique, but it was adapted to the other chromatographic techniques used in this work 
to purify FH8BMP-2. The purification protocol was performed by using a peristaltic 
pump and the different steps were followed by observation of the reaction with 
Bradford reagent (5 µl Bradford + 200 µl sample). 
The stages relative to the recovery of the soluble fraction (ressuspension of cell 
pellet, enzymatic and mechanical cell lysis) are described in section 2.5.1 and 2.5.3. The 
detailed HIC protocol is described below and it is important to refer that all the 
procedure was performed at 4 ºC. 
 
1. The 5 ml prepacked column Phenyl Sepharose™ 6 Fast Flow (high sub) was 
stored in 20% ethanol at 4 ºC. Prior to usage, the column was washed with water 
and it was determined the appropriate flow rate to apply during purification – 1 
ml/min to equilibration and washing steps; 0.5 ml/min to apply sample to the 
column and to elute target protein; 
2. The column was equilibrated with 5 CV1 of corresponding binding buffer; 
3. Soluble fraction, previously recovered, was applied onto the column (soluble 
fraction was previously filtered/centrifuged); 
4. The flowthrough sample was collected and aliquoted to be analyzed by SDS-
PAGE; 
5. The column was washed with at least 5 CV of corresponding washing buffer 
until the Bradford signal is low intense blue to ensure that all unbound material 
has washed out through the column. Washing samples of 10 ml were collected 
and aliquoted to be analyzed by SDS-PAGE; 
6. Target protein was eluted with corresponding elution buffer, and purified 
samples of 5 ml were collected in 15 ml tubes and aliquoted to be analyzed by 
SDS-PAGE; 
                                                          
1
 Buffer volumes used during sample application, washing, elution and re-equilibration are expressed in column volumes (CV). In 
this project were used columns with a 5ml of bed volume: for example 5 CV= 25 ml. 
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7. The cleaning procedure of the column after use was performed as following: 
column was washed with 2 CV of distillated water; impurities were removed 
with 8 M urea solution or 1 M NaCl; it was again washed with distillated water 
and finally the column was washed with 20% ethanol (usually 2 CVs); 
8. The column was stored at 4 ºC. 
 
2.7.2 Immobilized metal ion Affinity Chromatography (IMAC) 
 
IMAC separates proteins on the basis of a reversible interaction between target 
protein through histidine residues (or Trp and Cys) present on their surface and divalent 
metal ions (e.g., Ni
2+
, Cu
2+
, Zn
2+
, Co
2+
) immobilized via a chelating ligand. In the 
particular case of this study, nickel was used as immobilized ligand, which allows the 
affinity of histidines tail present in FH8BMP-2 protein. Immobilized metal ion Affinity 
Chromatography with nickel (IMAC-Ni) purification experiments involves the 
following steps: equilibration of the column with binding buffer containing a low 
concentration of imidazole, which is a counter ligand that binds to the immobilized 
nickel. Then sample is applied to the column, but before is adjusted to the same 
imidazole concentration; in this stage, proteins with histidines bind while displacing the 
imidazole counter ligands. The third step is column wash and then elution of the target 
protein using a higher concentration of imidazole. Instead of imidazole gradient, it is 
important to note that these experiments can also be performed using a pH gradient. 
Final step corresponds to column regeneration, when all molecules that still remained 
are removed. 
 
In this work, for purification of FH8BMP-2 it was used in small scale screenings 
a nickel Ni-NTA resin (GE Healthcare); in larger scale assays a prepacked 5 ml column 
HisTrap IMAC HP (GE Healthcare) was used. 
Tables 12 and 13 present the description of all buffers used in IMAC purification 
protocols performed in this study. The volumes used in each step of IMAC experiments 
are described below for the protocols used in small and larger scale assays. 
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Table 12: Buffers recipe for IMAC small screenings. 
 
Table 13: Buffers recipe for IMAC 0.5-1L purification assays. 
 
2.7.2.1 Small scale screenings protocol 
 
The general protocol followed in these purification screenings was the same to 
the described in section 2.7.1.1. In this section it only will be described the main 
differences registered to the case of IMAC experiments: 
 Soluble fraction was adjusted, by adding imidazole at 20 mM of concentration; 
 In screening 3, it was used only 300 µl of resin solution, and consequently the 
buffer volume applied in each step was 300 µl. 
        IMAC - Small scale Screenings 
 
Incubation 
conditions 
Screening Target protein 
Lysis 
Buffer 
Binding 
Buffer 
Washing 
Buffer 
Elution 
Buffer 
Time ºC 
Screening  1 pQE-30/FH8BMP-
2 
50 mM Tris, 
250 mM 
NaCl, pH 8 
 
50 mM Tris, 
250 mM 
NaCl, 20 
mM 
imidazole, 
pH 8 
50 mM Tris, 
250 mM NaCl, 
40 mM 
imidazole, pH 
8 
50 mM Tris, 
250 mM 
NaCl, 300 
mM 
imidazole, 
pH 8 
2h 4 
Screening 2 pQE-30/FH8BMP-
2 
50 mM Tris, 
250 mM 
NaCl, pH 8 
 
50 mM Tris, 
250 mM 
NaCl, pH 8 
50mM Tris, 
250mM NaCl, 
pH 6.5 
 
50 mM Tris, 
250 mM 
NaCl, pH 4.0 
2h 4 
Screening 3 pETM/FH8BMP-2 50 mM Tris, 
250 mM 
NaCl, pH 
7.4 
 
50 mM Tris, 
250 mM 
NaCl; 20 
mM 
imidazole, 
pH 7.4 
50 mM Tris, 
250 mM NaCl; 
40 mM 
imidazole, pH 
7.4 
 
50 mM Tris, 
250 mM 
NaCl; 300 
mM 
imidazole, 
pH 7.4 
30 
min 
4 
IMAC - 0.5-1L Purification Assays 
Purification 
assay 
Target protein Lysis Buffer 
Binding 
Buffer 
Washing Buffer Elution Buffer 
Assay 1 pETM/FH8BMP-2 50 mM Tris, 
250 mM NaCl, 
pH 7.4 
50 mM Tris, 
250 mM 
NaCl; 20 mM 
imidazole, 
pH 7.4 
50 mM Tris, 250 
mM NaCl; 40 mM 
imidazole, pH 7.4 
 
50 mM Tris, 250 
mM NaCl; 300 
mM imidazole, 
pH 7.4 
Assay 2 pStaby1.2/FH8BMP-
2 
50 mM 
Naphosphate, 
300 mM NaCl, 
pH 7.4 
 
50 mM 
Naphosphate, 
300 mM 
NaCl, pH 7.4, 
20 mM 
imidazole 
50 mM 
Naphosphate, 300 
mM NaCl, pH 7.4, 
40 mM imidazole 
 
50 mM 
Naphosphate, 
300 mM NaCl, 
pH 7.4, 300 mM 
imidazole 
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2.7.2.2 0.5-1L Purification Assays protocol 
 
As referred before, the HIC purification protocol is similar to the adapted for 
IMAC assays and so the steps performed in these experiments can be consulted in 
section 2.7.1.2. 
 
2.7.3 Ion Exchange (IEX) chromatography  
 
Ion exchange (IEX) chromatography can separate molecules, like proteins, on 
the basis of slight differences in their surface charge. In the specific case of proteins, 
they are formed by different amino acids containing acid and basic groups and 
consequently their net surface charge will change according to changes in pH 
environment 
[46]
. Relationship between net surface charge and pH is unique for a 
specific protein and a model of this relationship can be visualized in Figure 8.  
Considering this feature, in an IEX separation, a reversible interaction between 
charged molecules and an oppositely charged chromatography media occurs to ensure 
that the target molecules or proteins bind to the medium while they are loaded onto the 
column.  
 
Figure 8: Variation of surface net charge according to pH of the medium
 [46]. 
 
An IEX medium is formed by a matrix of spherical particles alternated with 
ionic groups that are negatively (cationic exchange) or positively (anionic exchange) 
charged. Matrix porosity is important to give a high internal surface area. In the first 
  Materials and Methods 
35 
 
step of IEX chromatographic technique, which corresponds to column equilibration, the 
pH and ionic strength of the binding buffer are selected to ensure that, when sample is 
loaded, proteins of interest bind to the medium and as many impurities as possible do 
not bind. Then conditions are altered so that proteins are eluted differentially. The 
elution step can be performed in two different ways: continuous gradient or a stepwise 
increase in ionic strength. This last type of elution is commonly made using NaCl. On 
the other hand, conditions can be chosen to maximize the binding of contaminants and 
in this way target protein is conducted to pass through the column and is recovered in 
the flowthrough sample without contaminants. This last strategy was performed in this 
study to recover FH8BMP-2 protein in the flowthrough sample. The removal of 
contaminants was conducted using a stepwise elution. To perform the IEX technique, an 
anionic exchanger incorporated in a prepacked 5 ml column HiTrap Q HP (GE 
Healthcare) was used. The purification protocol was performed by using a peristaltic 
pump and the different steps were followed by observation of the reaction with 
Bradford reagent (5 µl Bradford + 200 µl sample). The detailed IEX protocol is 
described below and all the procedure was performed at 4 ºC. Table 14 presents the 
composition of buffers used during this procedure: 
1. The column was washed with 2 CV of distillated water; 
2. The column was equilibrated with 5 CV of corresponding binding buffer at a 
flow-rate of 1 ml/min; 
3. Soluble fraction of FH8BMP-2 protein was applied onto the column (soluble 
fraction was filtered/centrifuged before being applied to the column) at a flow-
rate of 0.5 ml/min; 
4. The flowthrough sample was collected and aliquoted for SDS-PAGE; 
5. Column was washed with at least 5 CV of binding buffer, at a flow-rate of 
1ml/min, until the Bradford signal is low intense blue to ensure that all unbound 
material has washed through the column. Washing samples of 10 ml were 
collected and aliquoted to be analyzed by SDS-PAGE; 
6. Step gradient elution procedure (at a flow-rate of 0.5 ml/min) was made using 
NaCl, as described in Table 14; 
7. The cleaning procedure of the column after use was performed as following: 
column was washed with 2 CV of distillated water; impurities were removed 
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with 1M NaCl; it was again washed with distillated water and finally column 
was washed with 20% ethanol (usually 2 CVs); 
8. Column was stored at 4 ºC. 
 
Table 14: Buffers recipes for IEX chromatography. 
 
2.8 Protein dialysis  
 
After purification, it was necessary to perform the dialysis of all obtained protein 
samples, to return to the physiological pH. In this way, protein samples were dialysed in 
1x PBS buffer (prepared from 10x PBS concentrated buffer) at pH 7.4. Mostly, the 
dialysis procedure occurred overnight at 4 ºC. 
 
2.9 Protein quantification 
 
Protein quantification was performed by the Bradford colorimetric method with 
protein assay dye reagent (Biorad) in microplate. The protocol was done using plates of 
96 wells, where 10 µl of total protein sample was loading in each well with 200 µl of 
BioRad Protein Assay diluted 1:5. After 5-10 min it was measured the absorbance at 
595 nm, using the Biotech Synergy HT Microplate Reader. In each quantification test, a 
calibration curve was obtained measuring the absorbance at 595 nm of known 
concentrations of bovine serum albumin (BSA). 
 
 
Binding buffer 50mM Tris, 100mM NaCl, pH 8 
Step gradient elution 1. 50 mM Tris, 200 mM NaCl, pH 8 
2. 50 mM Tris, 400 mM NaCl, pH 8 
3. 50 mM Tris, 600 mM NaCl, pH 8 
4. 50 mM Tris, 800 mM NaCl, pH 8 
5. 50 mM Tris, 1 M NaCl, pH 8 
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2.10 Dynamic light scattering (DLS) 
 
DLS measurements were obtained in the Zetasizer Nano ZS (Malvern 
Instruments). The FH8BMP-2 protein concentration was in the range of 0.5-1 mg/ml 
and protein samples were centrifuged and filtered before measurements to remove any 
aggregates.  
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Chapter 3: Results and Discussion 
 
The present section is divided into four main parts: in the first part, the test of 
soluble expression and purification of recombinant FH8BMP-2 in E. coli M15 using the 
pQE-30 system (construction already available) is presented and discussed; secondly, 
the construction of recombinant vectors (pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2) 
is also discussed, followed by the test of soluble expression of recombinant protein in 
these new vectors. In the fourth part, the large scale production, purification and 
quantification of recombinant FH8BMP-2 in pETM and pStaby1.2 systems is presented 
and discussed.  
 
3.1 Soluble expression and purification of recombinant FH8BMP-2 in E. 
coli using the pQE-30 system 
 
The results of the expression and purification of FH8BMP-2 in pQE-30 vector 
are here divided into two parts: the main results of soluble test expression of fusion 
protein, in comparison with BMP-2 without FH8 tag and HBMP-2 (BMP-2 fused to H 
tag), and the results of purification tests performed with FH8BMP-2, under native 
conditions. 
 
3.1.1 Soluble test expression of recombinant FH8BMP-2 in E. coli M15 using 
the pQE-30 system 
 
The bmp-2 gene was previously cloned into the pQE-30, pQEH and pQEFH8 
plasmids and these vectors were first used in this study to assess the improvements in 
the BMP-2 soluble recombinant production in E. coli. The direct comparison between 
the soluble expression of BMP-2 and HBMP-2 proteins is presented in Figure 9. As can 
be seen, through the box marked in both SDS-PAGE gels of the Figure (corresponding 
to soluble fractions), there is no expression of BMP-2 in soluble form at the expected 
molecular weight of 17 kDa (Figure 9.a) and for the case of HBMP-2 there is a minimal 
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expression in this state, at the expected molecular weight of 18.5 kDa (Figure 9.b). 
Therefore, the expression of both BMP-2 and HBMP-2 proteins occurs mainly in the 
insoluble form as observed in samples marked by a brown arrow. This result reflects the 
difficulty in obtaining BMP-2 protein in soluble form. 
 
 
Figure 9: a) 15%-4% SDS-PAGE solubility analysis of BMP-2 in pQE-30 system: 1 – soluble 
fraction; 2 – insoluble fraction; M - PageRuler™ protein marker (Fermentas). 
b) 15%-4% SDS-PAGE solubility analysis of HBMP-2 in pQE-30 system: M - PageRuler™ protein 
marker (Fermentas); 1 – insoluble fraction; 2 - soluble fraction. 
 
 
Figures 10 and 11 present, respectively, the SDS-PAGE gels of induction and 
soluble expression analysis of recombinant protein BMP-2 fused to the FH8 tag, 
obtained in 250 ml cultures. This analysis allowed to access if the induction process 
occurred and if the recombinant protein was expressed in soluble form. Taking into 
account the expression profiles in Figure 10, it is possible to observe after induction the 
expression of a protein around 25 kDa, which is in agreement with the estimated weight 
of FH8BMP-2 that corresponds to 25.13 kDa. An optimization of culture conditions for 
soluble expression of FH8BMP-2 protein was then conducted using four experiments 
(Table 15), testing different induction times and compositions of lysis buffer.  Buffer A 
corresponds to Tris composition and Buffer B to Sodium Phosphate composition 
(detailed composition of buffers are described in section 2.5.1 of materials and methods 
chapter).  
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Figure 10: 15%-4% SDS PAGE analysis of expression level of recombinant FH8BMP-2 in E. coli 
M15/pQE-30: M – PageRuler™ protein marker (Fermentas); 1 –uninduced total bacterial protein; 2 – 
induced total bacterial protein. 
 
Table 15: Studied culture conditions for soluble expression of FH8BMP-2. 
 
Figure 11 shows the SDS-PAGE of total lysate and soluble fraction samples 
obtained in the soluble expression optimization. Looking at the gel, it is possible to 
observe the expression of soluble FH8BMP-2 (lanes 2, 3, 6 and 7) at the same 
molecular weight as observed in the induction analysis (around 25 kDa). In general, the 
soluble expression is very similar in the four conditions tested. However, there is a 
slightly increase in band intensity for condition c) (Table 15), which is marked in Figure 
11 with a red arrow. This result confirms that the FH8 tag solubilises the expression of 
BMP-2 protein in E. coli, in comparison to the results obtained with the protein without 
tag. This result is in agreement with previous work showing that FH8 is a solubility tag 
[36,39]
. Regarding the induction conditions tested, the 16h was the most favourable 
condition and so, it was selected to further proceed with large scale production. In 
relation to the type of buffer, the lysis buffer A shows better results for soluble 
expression of the fusion protein. Nevertheless, it was decided to proceed with the two 
Culture conditions Description 
a) Induction time: 16h 
Lysis buffer: Buffer B 
b) Induction time: 24h 
Lysis buffer: Buffer B 
c) Induction time: 16h 
Lysis buffer: Buffer A 
d) Induction time: 24h 
Lysis buffer: Buffer A 
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buffer compositions in further experiments to study the conformation behaviour and 
stability of the fusion protein.  
 
 
Figure 11: SDS-PAGE Solubility analysis of FH8BMP-2 in pQE-30 system of 250 ml cultures: M – 
PageRuler™ protein marker (Fermentas); 1 – total lysate of a); 2 – soluble fraction of a); 3 – soluble 
fraction of b); 4 – total lysate of b); 5 – total lysate of c); 6 – soluble fraction of c): monomer of 
FH8BMP-2 – red arrow; oligomer of FH8BMP-2 – white arrow; 7 – soluble fraction of d); 8 – total lysate 
of d). 
 
In Figure 11 it is also observed a gel band in all soluble samples around 50 kDa 
(indicated by a white arrow). The intensity of this band is relative high comparing to 
others of crude extract of E. coli, and for that reason, it may correspond to an oligomer 
of FH8BMP-2, which have an estimated molecular weight of approximately 50 kDa. 
The formation of a oligomeric form can be related to the native conformation of BMP-2 
in homodimer 
[11,16]
. Interestingly, comparing this result to the previous one of the 
HBMP-2 solubility analysis, it is possible to observe a similar band close to 40 kDa for 
insoluble HBMP-2, which may also correspond to an oligomeric form (estimated at 
around 37 kDa). This can indicate conformational changes of BMP-2 in the presence of 
the fusion tag.  BMP-2 is a protein that is biologically active in homodimeric form and 
the presence of the tag, can possibly help to acquire this conformation. However, it is 
necessary to perform an immunoblotting assay to prove that the protein bands around 50 
kDa detected in the gel correspond to BMP-2 protein.  
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3.1.2 Small screening purification test of soluble recombinant FH8BMP-2 
produced in E. coli M15 using the pQE-30 system 
 
Small scale purification assays were performed using FH8BMP-2 soluble 
samples of previous expression experiments. The small screening of purification 
embraced two purification techniques: HIC and IMAC-Ni. Figure 12 presents the HIC 
results using the buffers recipe described in section 2.7.1 of materials and methods. In 
the first two assays (see assays 1 and 2 from Table 10 of that section), which involved 
Tris composition buffer and Sodium Phosphate composition buffer at pH 8 (previously 
tested in solubility analysis), results were not satisfactory because large amount of target 
protein was lost in the flowthrough and washing samples, but the FH8BMP-2 was still 
recovered in the elution step, as seen in Figure 12.a (gel band around 25 kDa). The 
purity level of the obtained fusion protein was low as a large amount of contaminants 
are present in the eluted sample. These results showed an unspecific interaction of 
FH8BMP-2 with resin ligands that can be justified by the presence of strong hydrophilic 
residues of FH8BMP-2 (hidrophobicity analysis is shown in appendix 2). The 
hydrophilic nature of this protein can promote a weak interaction between protein and 
hydrophobic resin.  
Taking into account the results obtained in assays 1 and 2, two different 
approaches were tested in order to improve the interaction of FH8BMP-2 with the HIC 
media. In the first strategy, the exposure of hydrophobic residues of FH8BMP-2 was 
promoted by the addition of calcium (CaCl2) to the soluble fraction before being applied 
onto the purification column. This strategy was selected due to the calcium binding 
properties of FH8 protein and previous work that demonstrate a larger solvent exposed 
hydrophobic region of FH8 in the presence of calcium 
[38,39]
. In the second strategy, two 
pH values for the purification buffers were studied (7 and 7.5) using the Tris 
composition (see assays 3 and 4 from Table 10 of materials and methods). Figures 
12.b1 and 12.b2 show the SDS-PAGE analyses of purification samples from these 
assays, where condition i corresponds to pH 7 and condition ii corresponds to pH 7.5 of 
binding/washing buffer. Regarding to purification results, it is possible to detect 
important improvements in relation to the previous purification assays: reduction of 
protein loss in flowthrough and washing samples (Figure 12.b2) and reduction of 
contaminants level in elution samples (Figure 12.b1). These improvements 
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demonstrated an increased and specific interaction between protein and hydrophobic 
resin that can be explained by the calcium-dependent conformation change of FH8 tag.  
 
 
Figure 12: 15%-4% SDS-PAGE analysis of samples obtained from HIC small scale purification 
assays of FH8BMP-2: 
a) Sampling of HIC assays 1 and 2: M - PageRuler™ protein marker (Fermentas); 1 – flowthrough 
sample; 2 – eluted sample.  
b1) Eluted samples of HIC assays 3 and 4: 1 – soluble protein sample charged into the column; 2,5,6,9 
– eluted samples from i; 3,4,7,8 - eluted samples from ii. 
b2) Flowthrough and washed samples of HIC assay 3 and 4: 1,4 - washed samples from ii; 2,3 - 
washed samples from i; 5  - flowthrough sample from ii; 6 – flowthrough sample from i. 
 
The purity achieved was not optimal, yet. Regarding the pH strategy, the best 
results were achieved with the binding buffer at pH 7, where it is verified a stronger 
protein recovery in eluted samples marked with a red box in Figure 12.b1.  
The HIC small screenings outlined the calcium importance for the hydrophobic 
interaction of FH8BMP-2 fusion protein and a HIC buffer was established to proceed to 
larger scale purification assays (Table 16).  
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Table 16: Recipe of buffers of HIC purification step of recombinant FH8BMP-2 protein in E. coli 
M15/pQE-30. 
 
In order to explore the fusion protein purification using the 6 histidines 
presented in the N-terminal of FH8BMP-2, an affinity chromatography using IMAC-Ni 
technique was performed. The main results of this assay using an imidazole gradient 
(see screening 1 from Table 12 of materials and methods) are present in Figure 13. 
Comparing with the previous HIC purification results, notable differences are 
highlighted, since it can be observed a much lower interaction between FH8BMP-2 and 
nickel resin. This result is identified in Figure 13 by the reduced amount of protein in 
eluted samples (marked by a yellow box) and as indicated by a red arrow, the majority 
of protein amount leaves the column in flowthrough sample. The poor purification of 
FH8BMP-2 by IMAC can be possibly explained by the fusion protein conformational 
complexity. The oligomeric tendency of both FH8 tag and BMP2 protein can be hiding 
the histidines tail and consequently, decreasing the protein interaction with nickel ions.  
As the FH8BMP-2 was better purified by HIC than by IMAC, the HIC technique 
was chosen for the fusion protein purification in larger scale experiments. 
 
 
 
 
 
 
 
 
 
 
Figure 13: 15%-4% SDS-PAGE analysis of samples obtained from IMAC-Ni small scale 
purification assay: M - PageRuler™ protein marker (Fermentas); 1 - soluble protein sample charged into 
the column; 2-5 – eluted samples; 6 – flowthrough sample; 7-9 – washed samples. 
Lysis buffer Binding buffer Washing buffer Elution 
buffer 
Additives 
50 mM Tris, 250 
mM NaCl, pH 7 
50 mM Tris, 
NaCl 250 mM, 
pH 7 
50 mM Tris, 250 
mM NaCl, pH 7 
Dilution 1:2 
50 mM Tris, 
pH 10 
5 mM of 
CaCl2 
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3.1.3 Larger scale purification test of soluble recombinant FH8BMP-2 in E. 
coli M15 using the pQE-30 system  
 
Figure 14 shows the SDS-PAGE results of large scale HIC purification assays 
involving E. coli 1 L culture of FH8BMP-2 and using the buffer composition selected in 
small scale tests (Table 16). As can be seen in Figure 14.a1, the total lysate (lane 1) 
contains an intense band around 25 kDa, which corresponds to FH8BMP-2 monomer. 
In contrast, in the soluble fraction applied onto HIC purification column (lane 2), an 
intense gel band with approximately 50 kDa (indicated by a red arrow) is also detected, 
in addition to a slight gel band around 25 kDa (indicated by a white arrow). This result 
is in agreement with previous observations for the soluble expression of FH8BMP-2, in 
which two gel bands (25 and 50 kDa) were observed. Curiously, in this larger scale 
expression, the 25 kDa gel band is obtained in lower intensity than the 50 kDa gel band. 
Regarding the eluted samples presented in Figure 14.a2, it is possible to observe the 
elution in high amounts of a protein with 50 kDa. The reduced loss of protein in 
flowthrough and washing samples (Figure 14.a1) contributed to this high protein 
amount during the elution step. The possible monomeric form of the protein (around 25 
kDa) is practically absent in SDS-PAGE, prevailing the possible dimeric state. In order 
to evaluate this type of conformation obtained by the fusion protein FH8BMP-2, a 
dynamic light scattering (DLS) analysis was performed. The hydrodynamic radius 
FH8BMP-2 after purification was measured and it was estimated a molecular weight of 
137.80 kDa that may correspond to a complex in pentamer form. This result is in good 
agreement with the SDS-PAGE analysis, in which were used denaturing conditions. 
Here, the possible pentamer form was denaturated, resulting in the observation of a gel 
band with a molecular weight corresponding to the dimeric form (50 kDa).  
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Figure 14: HIC purification assay of 1L E. coli M15/pQE-30 culture of FH8BMP-2: 
a1) 1 – total lysate; 2 - soluble protein sample charged into the column; M – PageRuler™ protein marker 
(Fermentas); 3 – flowthrough sample; 4-8 – washed samples; 9 – eluted sample. 
a2) 10-17 - eluted samples. 
 
Previous structural studies of the FH8 tag shows a high tendency of this protein 
for the formation of oligomers, in particular dimers and pentamers, which are also 
enhanced by the interaction of this molecule in solution with calcium 
[39,47]
. The 
formation of oligomers of the fusion protein FH8BMP-2 may, therefore, be explained 
by the oligomerisation tendency promoted by the FH8 tag. However, since it was 
already observed the presence of a 50 kDa band in solubility tests, even before the 
addition of calcium, it can be concluded that the transition to a pentamer complex 
occurs at an early stage. But calcium is in fact an enhancer of this conformational 
change, as aggregation of the protein in this state is very stable and more prevalent after 
the addition of calcium. The dynamic structure of the FH8 tag can be influencing the 
global conformation of the fusion protein, and different molecular forms of FH8BMP-2 
can be formed. Additionally, the monomer-to-dimer transition of BMP-2 itself can also 
be occurring at the same time, as there are proteins that in response to a change in 
calcium levels, undergo significant conformational changes and dimerize to form an 
active complex. These include the class of cell matrix proteins, which belongs the 
BMPs 
[48]
. Naturally, with these conformational changes, the establishment of 
hydrophobic paths can be favored by the exposure of hydrophobic areas of FH8 tag and, 
on the other hand, by the solvent-accessible surface of the BMP-2 dimer, which exposes 
large hydrophobic areas 
[11]
. With all of these possibilities it becomes clear the ability 
for interaction of the fusion protein with the hydrophobic resin in HIC purification 
column. 
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At the end of the purification assay, all eluted samples were dialyzed in PBS 1X, 
pH 7.4 and then grouped and quantified by Bradford method (described in section 2.9 of 
materials and methods). A final protein purification yield of 16 mg of purified 
FH8BMP-2 per litre of E coli culture was obtained using the FH8/HIC methodology.  
In order to improve purity of protein samples, a second HIC step was performed 
with eluted fractions 10 and 11 from Figure 14.a2, using the same protocol as 
previously. The results of this assay are presented in Figure 15.  As observed, the 
second HIC purification improved the purity level of FH8BMP-2. The high stability of 
FH8BMP-2 aggregation form and the specific interaction with hydrophobic resin, 
increased by the effect of calcium, was also evident from this second HIC purification. 
A final yield of 4.85 mg of purified protein per liter of E. coli was obtained. This lower 
yield in comparison to the first HIC purification can be explained by the loss of protein 
during dialysis process and during the second purification step itself.  
 
 
 
 
 
 
 
 
 
 
 
Figure 15:Second HIC purification of eluted samples of first HIC assay containing recombinant 
FH8BMP-2: M – PageRuler™ protein marker (Fermentas); 1-6 – eluted samples. 
 
From this first stage of the project, important conclusions can be taken:  
 The FH8 allows the solubilisation of BMP-2 protein, and here, a new 
strategy was developed to overcome a limitation in obtaining bone 
morphogenetic protein in soluble form. 
 With the purification strategy studied, it was possible to find new 
directions to purify the fusion protein, namely by the FH8 tag in combination of 
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calcium and HIC technique. Therefore, it was possible to use the FH8 tag as a 
purification tag in addition to its solubility enhancer effect. 
 A good purity level of protein samples was achieved, but it is still 
necessary to increase the amount of soluble expression and consequently the 
amount of purified protein for future biomedical applications. 
 The FH8BMP-2 purification by affinity chromatography with nickel was 
not successful possibly due to an inaccessibility of histidines tail caused by the 
global structure of the fusion protein. 
 
3.2 Cloning of bmp-2 gene into pETMFH8 and pStaby1.2FH8 plasmids 
 
In order to increase the production of soluble protein FH8BMP-2 and to obtain 
larger quantities of purified protein for biomedical applications, two different 
expression systems were also studied in this work: the pETMFH8 and the 
pStaby1.2FH8  
 Figure 16 presents the steps followed to obtain the desired constructs. As it can 
be seen from Figure 16.a, the template sequence used to produce BMP-2 fragment by 
PCR was the coding region of the mature BMP-2 from the construction pQE-30/BMP-
2. The PCRs performed allowed to amplify the interest fragment and to insert in its ends 
the cleavage sites of restriction enzymes NcoI and XhoI (for cloning into pETMFH8) 
and SacI and XhoI (for cloning into pStaby1.2FH8). Before performing this step it was 
important to verify if the selected restriction enzymes (they were chosen according to 
the MCS of vectors pETM10FH8 and pStaby1.2FH8) do not cut the bmp-2 fragment. 
According to NebCutter analysis (shown in appendix 3), none of these enzymes cut the 
fragment of interest. The sequence of primers used is presented in section 2.4.2 of 
materials and methods. In relation to the constructions, it is important to notice the 
difference of the location of FH8 tag and histidines tail between them. Due this 
difference, for the cloning process of bmp-2 gene into vector pStaby1.2FH8 it was 
necessary to introduce a mutation in the natural codon stop of the sequence of BMP-2 to 
allow expression of the histidines tail located at the C-terminal. 
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PCR and purification of PCR products 
Cloning into pETM10FH8 
Cloning into pStaby1.2FH8 
pQE30BMP2 - template sequence 399bp 
Digestion of fragments with restriction enzymes 
(A) 
b) 
Plasmid DNA extraction 
Digestion of plasmids with restriction enzymes 
c) 
a) 
Figure 16: Cloning strategy to pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2 constructs. 
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The obtained PCR products were analysed in electrophoresis agarose gel and the 
results are present in Figure 17. Bands of PCR products are slightly above the band of 
400 bp, which is concordant with the predicted size, 428 bp (for cloning into 
pETMFH8) and 444 bp (for cloning into pStaby1.2FH8). It is possible to verify the 
inexistence of unspecific amplifications and that the intensity of DNA bands is higher 
for the fragment cloning into pETMFH8 (wells 5 and 6). This result is consistent with 
the DNA quantification performed which indicates the following DNA concentration: 
PCR product (pETMFH8) – 167 ng/µl and PCR product (pStaby1.2FH8) – 120 ng/µl. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: 1% Agarose electrophoresis analysis of bmp-2 PCR products: 1 – negative control of 
PCR; 2, 3 - amplified bmp-2 gene by PCR (for cloning into pStaby1.2FH8); M –NZYDNA Ladder III 
DNA marker; 4 - negative control of PCR; 5, 6 - amplified bmp-2 gene by PCR (for cloning into 
pETMFH8). 
 
PCR products were then purified and digested with the corresponding restriction 
enzymes. The plasmid DNAs were also digested and analyzed and purified in 1% 
agarose gel, as it can be seen in Figure 18. 
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Figure 18: 1% Agarose electrophoresis analysis of DNA plasmids: 1 - XhoI and NcoI double 
restriction enzyme digestion of pETMFH8 plasmid; M - NZYDNA Ladder III DNA marker; 2 - XhoI and 
SacI double restriction enzyme digestion of pStaby1.2FH8 plasmid. 
 
As expected it can be visualized a unique band for pETMFH8 vector, 
corresponding to the linearized vector with 5.5 Kbp, approximately. For the 
pStaby1.2FH8 plasmid digestion, it is possible observe a faint bad around 200 bp, 
which corresponds to CP12 fragment, as the plasmid DNA of pStaby1.2FH8 was 
isolated from a culture plate of pStaby1.2/FH8CP12. The band corresponding to 
linearized vector has a size slightly above 6 Kbp, closer to the predicted size of plasmid 
pStaby1.2FH8 that is 6.11 Kbp. 
Figure 19 shows the obtained colony PCR products of transformants for the two 
recombinant vectors. All clones of pETM/FH8BMP-2 are positive, as bands are located 
just above 800 bp and this result is consistent with the predicted size of PCR product of 
848 bp. Unspecific amplifications that can be observed in agarose gel may be related to 
the use of universal primers used in PCR colony. For the case of pStaby1.2FH8BMP-2 
only the clone 3 is positive with an estimated size of 816 bp (in agarose gel the clone 
band is very close to 800 bp band). Similar unspecific amplifications can be also 
detected in this transformation result. Clone 8 of pETM/FH8BMP-2 was chosen for 
sequencing to be the one that has a higher level of purity, and for obvious reasons clone 
3 of pStaby1.2/FH8BMP-2 was selected to be sequenced. 
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Figure 19: 1.2% Agarose electrophoresis analysis of transformants of recombinant vectors: a) 
Transformants of pETMFH8BMP-2: 0 – transformation negative control; M - NZYDNA Ladder III 
DNA marker; 1-8 – pETMFH8BMP-2 clones. b) Transformants of pStaby1.2FH8BMP-2: M - 
NZYDNA Ladder III DNA marker; 0 – transformation negative control; 1-3 – pStaby1.2FH8BMP-2 
clones.  
 
 
The sequencing results were analysed by the BLASTN tool (NCBI). This 
analysis showed that the sequence of both clones presents 100% of identity with the 
bone morphogenetic protein 2 from Homo sapiens (accession number EAX10386.1) 
and 100% of identity with putative calcium binding protein from Fasciola hepatica 
(accession number AAF31420.1). A summary of this analysis is presented in appendix 
4. 
In the next step, E. coli BL21 Codon Plus Ril, Rosetta2 and SE1 expression 
strains were transformed with the sequenced positive clones of recombinant vectors. It 
is important to refer that obtained clones of this transformation were also analyzed by 
colony PCR and then a clone of each transformation was selected for the FH8BMP-2 
expression study.  
 
3.3 Soluble expression and purification of recombinant FH8BMP-2 in E. 
coli using pETMFH8 and pStaby1.2FH8 systems 
3.3.1 Small scale screening 
 
The expression of recombinant FH8BMP-2 protein using pETM and pStaby1.2 
vectors was first evaluated in a small scale screening (20 ml cultures), testing two 
induction conditions (Table 17) and two different E. coli stains (Codon Plus Ril and 
Rosetta2) for pETM or the E. coli SE1 strain for pStaby.  
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Table 17: Induction conditions of screening tests for soluble expression of recombinante FH8BMP-2. 
Type of condition Description of induction conditions 
i 30ºC; 3-4h; [IPTG] - 0.5 mM 
ii         20ºC; o/n; [IPTG] - 0.2 mM 
 
 
Figure 20 presents the results of soluble expression of pETM/FH8BMP-2. It is 
possible to verify in lanes 4 and 5 of both gels the expression of a protein with a 
molecular weight around 25 kDa, which corresponds to the estimated weight of 
FH8BMP-2 in this expression system (25.02 kDa). A band of molecular weight close to 
15 kDa, which appears with significant intensity, corresponds to lysozyme, which was 
used in the lysis buffer. As can be observed from Figure 20, solubility of fusion protein 
is achieved with both induction conditions, using the two strains. However, the 
expression of soluble fusion protein is higher for the condition of induction at 20 °C, 
marked by a red arrow. This result is in agreement with literature, which states that 
lowering the expression temperature routinely improves the solubility of recombinant 
expressed proteins in E. coli, especially with proteins that are difficult to express in this 
bacteria, which is the case of BMP-2 protein 
[21]
. Comparing the two strains tested, it is 
possible to note that the soluble expression results are very similar, as both strains 
promote the efficient expression of rare codons 
[21]
. Nevertheless, it is possible to 
determine a slight increase of solubility when using the BL21 Codon Plus Ril strain.  
 
Figure 20: 15%-4% SDS-PAGE solubility analysis of FH8BMP-2 in pETM system in 20 ml 
cultures: a) E. coli BL21 Codon plus Ril culture: M – PageRuler™ protein marker (Fermentas); 1 –
uninduced total bacterial protein; 2 – induced total bacterial protein of i); 3 – total lysate of i); 4 – soluble 
fraction of i); 5 – soluble fraction of ii); 6 – total lysate of ii); 7 - induced total bacterial protein of ii). 
 b) E. coli Rosetta 2 culture: 1 –uninduced total bacterial protein; M – PageRuler™ protein marker 
(Fermentas); 2 – induced total bacterial protein of i); 3 – total lysate of i); 4 – soluble fraction of i); 5 – 
soluble fraction of ii); 6 – total lysate of ii); 7 - induced total bacterial protein of ii). 
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The BL21 Codon Plus Ril strain and condition ii were selected for the large 
scale production and subsequent purification of FH8BMP-2.  
Prior to the large scale experiments, it is important to analyze the results shown 
in Figure 21, which demonstrate a comparison between the total lysate and soluble 
fraction samples of the following proteins: FH8BMP-2 expressed using the pETMFH8; 
HisBMP-2 expressed using the pETM11 and proteins expressed using the 
corresponding empty vectors without BMP-2 protein (pETM/FH8 and pETM/His), 
which function as a negative control for the BMP-2 expression. 
 
 
Figure 21: 15%-4% SDS-PAGE solubility analysis of pETM/FH8BMP-2; pETM/HisBMP-2; 
pETM/FH8 and pETM/His samples: 1 - total lysate of pETM/His; 2 – soluble fraction of pETM/His; 3 
– total lysate of pETM/HisBMP-2; 4 – soluble fraction of pETM/HisBMP-2; 5 – soluble fraction of 
pETM/FH8BMP-2; 6 – total lysate of pETM/FH8BMP-2; 7 – soluble fraction of pETM/FH8; 8 – total 
lysate of pETM/FH8; M – PageRuler™ protein marker (Fermentas).  
 
Analyzing the gel of Figure 21, it is possible to observe in all lanes of the gel a 
band with the molecular weight similar to FH8BMP-2 (between 20 and 30 kDa). As this 
band is also present in the empty vectors pETM/FH8 and pETM/His, it corresponds to a 
protein from the crude extract of E. coli. The expression of the protein in lane 5 of the 
gel corresponds in fact to the soluble fusion protein FH8BMP-2. FH8 solubilises the 
BMP-2 as shown by the comparison between soluble fractions of HisBMP-2 and 
FH8BMP-2 (lanes 4 and 5). These observations are in good agreement with the results 
obtained with FH8BMP-2 and BMP-2 expressed proteins using pQE-30 vector 
described in section 3.1.1 of present chapter. 
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Figure 22 shows the SDS-PAGE analysis of the main results of FH8BMP-2 
soluble expression test using the pStaby1.2 system. Lanes 1, 10, 15 and 18 correspond 
to proteins expressed using the empty pStaby1.2/FH8 vector. None of these lanes 
present relevant protein expression around 25 kDa, which is the estimated molecular 
weight for FH8BMP-2 using this system. The total lysate samples (lanes 8 and 9) of 
FH8BMP-2 expression using the two conditions tested contain two proteins between 
20-30 kDa. Looking at soluble fractions, it is possible identify the expression of a 
protein with a molecular weight higher than 25 kDa, at 20 ºC. On the other hand, at the 
same temperature, a protein around 25 kDa is expressed in insoluble form. The both 
bands referred are indicated by a red arrow and are correspondent to bands identified in 
total lysate samples. The samples of soluble and insoluble fractions were analysed by 
Western blot (data not shown) and the results are in agreement with what it is observed 
in Figure 22. Both bands visualized correspond to FH8BMP-2 but present indeed a shift 
in the molecular weight. The condition ii was selected for further larger scale 
productions. 
 
 
 
Figure 22: 15%-4% SDS-PAGE Solubility analysis of FH8BMP-2 in pStaby1.2 system in E. coli 
SE1 20 ml cultures in comparison with pStaby1.2/FH8 (negative control –without protein):  
1-4,10,15-18: culture samples of pStaby1.2/FH8: 1 –total lysate of ii; 2 - uninduced total extract; 3 – 
induced total extract of ii; 4 - induced total extract of i; M – PageRuler™ protein marker (Fermentas); 10 
– total lysate of i; 15 – soluble fraction of ii; 16 - insoluble fraction of ii; 17 – insoluble fraction of i; 18 – 
soluble fraction of i. 
 5-9,11-14: culture samples of pStaby1.2/FH8BMP-2; 5 –uninduced total bacterial protein; 6 – induced 
total bacterial protein of i); 7 -  induced total bacterial protein of ii); 8 – total lysate of ii; 9 – total lysate 
of i; 11 – soluble fraction of i); 12 – insoluble fraction of i); 13 – insoluble fraction of ii); 14 -  soluble 
fraction of ii. 
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3.4 Larger scale production and purification tests of soluble 
recombinant FH8BMP-2 in E. coli using pETM system 
 
This section is divided in three parts according to the different 
chromatographic techniques applied to purify the FH8BMP-2 fusion protein: 
immobilized nickel ion affinity chromatography (IMAC-Ni); hydrophobic interaction 
(HIC) and ion exchange (IEX) chromatography. 
 
3.4.1 Immobilized nickel ion affinity chromatography (IMAC-Ni) 
 
In the first part of purification strategy with recombinant protein FH8BMP-2 
from pETM system, it was performed small scale purification tests, using buffers recipe 
described in Table 18 and a more detailed description of incubation conditions can be 
consulted in section 2.7.2 of materials and methods. As it can be seen, similarly to 
assays performed with pQE-30/FH8BMP-2 it was used an imidazole gradient in the 
purification process. Samples obtained with this assay were analysed by SDS-PAGE 
and the gel is presented in Figure 23. By the observation of the gel, it is possible to 
conclude that the interaction between fusion protein and nickel resin was weak, as most 
of protein leaves the column in the flowthrough sample. As occurred with the 
FH8BMP-2 in pQE-30 system, the fusion protein structure may be hiding the histidines 
tail present in the N-terminal sequence of BMP-2.  
In this way, the purification strategy was targeted to the HIC technique in order 
to improve the results by the properties of the FH8 tag.  
 
Table 18: Recipe of buffers used in IMAC-Ni purification step of recombinant FH8BMP-2 protein in E. 
coli BL21 Ril/pETM. 
 
Lysis buffer Binding buffer Washing buffer Elution buffer 
50 mM Tris, 250 
mM NaCl, pH 7.4 
50 mM Tris, NaCl 250 
mM, 
20 mM imidazole, pH 
7.4 
50 mM Tris, 250 mM 
NaCl, 
40 mM imidazole, 
pH 7.4 
50 mM Tris, 250 
mM NaCl; 300 
mM imidazole, 
pH 7.4 
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Figure 23: 15%-4% SDS-PAGE analysis of samples obtained from IMAC-Ni small scale 
purification assay: M - PageRuler™ protein marker (Fermentas); 1 - soluble protein sample charged into 
the column; 2 - flowthrough sample; 3, 4 – washed samples; 5-7 – eluted samples. 
 
3.4.2 Hydrophobic interaction chromatography 
 
To perform the purification of FH8BMP-2 expressed in E. coli BL21 Codon 
Plus Ril, the previous results of purification of the fusion protein into the vector pQE-30 
were taken into consideration, in which there was a good interaction of the FH8 fused 
protein with the hydrophobic resin after the addition of calcium. Table 19 shows the 
buffers used in this step and as it can be seen the concentration of calcium used in 
soluble fraction was the same as that used in previous tests. SDS-PAGE gels of Figure 
24 shows samples from 1L of E. coli Codon plus BL21 Ril culture of pETM/FH8BMP-
2 and the results of the first purification step performed with the soluble fraction 
recovered from this production. 
 
Table 19: Recipe of buffers used in first HIC purification step of recombinant FH8BMP-2 protein in E. 
coli BL21 Ril /pETM. 
 
Lysis buffer Binding buffer Washing buffer Elution 
buffer 
Additives 
50 mM Tris, 250 
mM NaCl, pH 
7.4 
50 mM Tris, 
NaCl 250mM, 
pH 7.4 
50 mM Tris, 250 
mM NaCl, pH 7.4 
Dilution 1:2 
50 mM Tris, 
pH 10 
5 mM of 
CaCl2 
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Figure 24: 15%-4% SDS-PAGE gel with samples of 1L of E. coli Codon plus BL21 Ril culture of 
FH8BMP-2 and HIC purification samples: 1 – total lysate; 2 – soluble fraction charged into 
purification column; M – PageRuler™ protein marker (Fermentas); 3 – flowthrough sample; 4,5 – 
washed samples; 6-16 – eluted samples. 
 
Comparing the samples of total lysate and soluble fraction in Figure 24, it is 
possible to observe that a high expression of the FH8BMP-2 protein in soluble form 
with a molecular weight of approximately 25 kDa. This result reflects, but on a larger 
scale, the results from the small-scale analysis. Now, regarding the results of HIC 
purification performed, it is possible to see that there is loss of fusion protein in the 
flowthrough and washed fractions (lanes 3 and 4). However despite this loss, a high 
amount of protein is eluted in the first fractions (lanes 6 and 7) with high amount of 
contaminants. However, from the eluted fraction 10 it can be observed a good profile of 
purity of the recombinant protein. In relation to the presence of contaminants, they are 
not completely eliminated and their presence is more substantial in a molecular weight 
above the FH8BMP-2 band.  
At the end of the purification assay, all eluted samples were dialyzed in PBS 1X, 
pH 7.4 and then they were grouped and quantified by Bradford method (described 2.9 
of materials and methods). A final protein purification yield of 31 mg of purified 
FH8BMP-2 per litre of E. coli culture was obtained using the FH8/HIC methodology. 
 
In order to understand the effect of calcium in the interaction of the fusion 
protein with hydrophobic resin, it was made a similar purification assay (using the same 
conditions described in Table 19) using 1L of E. coli Codon plus BL21 Ril culture of 
FH8BMP-2, but now with a lower calcium concentration (2 mM). The same profile of 
production, as well the first eluted samples, presented in the left gel of Figure 24, was 
observed, that is, a high expression and amounts of FH8BMP-2. The remaining eluted 
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samples of this second assay are shown in Figure 25 and it is equivalent to the right gel 
shown in Figure 24. Comparing the two gels with eluted samples, it is possible to 
observe that, with a lower concentration of calcium, the interaction between the 
FH8BMP-2 and the hydrophobic resin is weaker, due to higher level of contaminants 
identified in the samples of Figure 25. This result supports the previous findings 
registered on larger scale purification of fusion protein into the vector pQE-30, 
involving HIC technique and calcium effect. Since the fusion protein in vector pETM 
has also strong hydrophilic residues (the graph of the degree of hydrophobicity of the 
protein is shown in appendix 2), addition of calcium allows an increased exposure of 
hydrophobic regions of the fusion protein. This modification on hydrophobicity of the 
protein is certainly correlated with the conformational change of the structure of FH8 
tag. The binding of calcium to the EF-hand loops of FH8 tag triggers the opening of the 
structure, which exposes a large hydrophobic area, allowing in this way a more specific 
binding to hydrophobic resin 
[38]
.  
 
Figure 25: 15%-4% SDS-PAGE gel with HIC purification samples from 1L of E. coli Codon plus 
BL21 Ril culture of FH8BMP-2, with lower calcium concentration: 1-7 – eluted samples; M – 
PageRuler™ protein marker (Fermentas). 
 
Another aspect of the interaction of the fusion protein with calcium may be 
related to the exposure of the BMP2 to this reagent. According to some studies, the 
addition of calcium influences the adsorption of the protein to certain surfaces as 
hydroxyapatite 
[49]
. At the same time, a DLS analysis was performed using an eluted 
sample from Figure 24 to explore the previously described calcium effect as an 
enhancer of fusion protein aggregation for higher molecular weight forms. It was 
measured the hydrodynamic radius of FH8BMP-2 and it was concluded that the global 
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arrangement of fusion protein resulted in a molecular weight estimation of 64 kDa, 
which corresponds to an oligomer of about 2.58 units and this may correspond to a 
dimeric form of the protein. This is approximately half of the value obtained for the 
fusion protein expressed in E. coli M15 using the vector pQE-30 (about 5.5 units). Once 
again this result is in agreement with the SDS-PAGE analysis, in which it is visualized a 
band of 25 kDa as a result of denaturation of the dimeric complex. As referred before, 
the aggregation of the fusion protein can be a result of combined individual factors 
related to FH8 tag and BMP-2 protein and calcium can be an enhancer of this 
aggregation. Additionally, according to features of recombinant bone morphogenetic 
protein, its dimer formation involves three monomer variants and their combination can 
lead to at least six dimeric isoforms and all of them have proven to be active in vitro cell 
culture assay 
[50]
. So this possible dimeric form of the fusion protein is extremely 
relevant for its biological activity in cell culture applications 
[16,50]
.  
Given the previous results and for improving the elimination of contaminants in 
the first eluted fractions (indicated in left gel of Figure 24) which have a high soluble 
amount of FH8BMP-2, a second purification of these fractions in the HIC column was 
performed, with initial calcium concentration of 5 mM. The results of this second stage 
are shown in Figure 26. The results of this second purification show the removal of 
most impurities and unspecific proteins that bound to the resin, but some contaminants 
are still observed above the FH8BMP-2 band (with 25 kDa). 
 
 
 
 
 
 
 
 
 
 
Figure 26: 15%-4% SDS-PAGE gel with samples of second HIC purification performed with eluted 
samples obtained from first HIC purification assay: M – PageRuler™ protein marker (Fermentas); 1-8 
– eluted samples. 
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At the end of the purification assay, all eluted samples were dialyzed in PBS 1X, pH 7.4 
and then they were grouped and quantified by Bradford method. A total yield of 
purified protein of 15.15 mg per liter of E. coli was obtained which corresponds to a 
production yield of 16.14 mg of protein per g of cell dry weight. 
An important goal was successfully achieved with FH8BMP-2 protein in pETM system, 
that is, a significant increase in purification yield of the fusion protein. 
 
3.4.2.1 Optimization of HIC wash step 
 
In order to reduce the affinity of unspecific proteins during elution in HIC, various 
agents were tested to optimize the washing step of this purification technique. Table 20 
presents the washing buffers tested. The choice of these agents stemmed from a 
previous work on the optimization of the washing step in the HIC technique 
[51]
. 
Table 20: Washing buffers tested in HIC purification. 
Washing buffers 
W1 – distilled H2O 
W2 – 50 mM Tris, 250 mM NaCl, pH 7.4 + 2.5 M MgCl2 
W3 – 50 mM Tris, 250 mM NaCl, pH 7.4 + 1.5 M Urea + 5% glycerol 
 
As a negative control, it was used the initial washing buffer (denominated W0, 
corresponding to lane 1 in gel of Figure 27), which is described in Table 19. It is 
possible to verify in gel of Figure 27 that significant lost of target protein FH8BMP-2 
occurred (around 25 kDa) during the washing process of the column with W0 and W2 
buffers. The difference between these two buffers is the presence of magnesium 
chloride (MgCl2) which is a chaotropic salt that is employed to decrease protein 
retention on HIC stationary phases. However, the effect of this salt was not favorable 
for the purification of recombinant FH8BMP-2 protein, since its elution in washed 
sample with high amounts of contaminants was observed. This result is in agreement to 
what was tested in previous studies, which showed for other proteins fused to the FH8 
tag that action of MgCl2 in a concentration range of 1-3 M is liable to decrease the 
stability of the interaction of calcium binding protein with the HIC resin 
[39]
.  
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Regarding theW3 buffer, it is possible to verify that the removal of contaminants 
is minimal and comparing to W2, elution of the target protein is lower. The explanation 
of this effect is related with two factors: first, the urea concentration was not high 
enough to allow a decrease in the affinity of unspecific proteins with hydrophobic resin. 
According to previous work conducted for the optimization of HIC wash step, the most 
dramatic increase in elimination of non-specific proteins was observed with urea 
concentrations above 2.0 M 
[51]
. Since the aim of this study is to work with FH8BMP-2 
protein in the native state, high concentrations of urea were not used. Secondly, with the 
synergistic effect of glycerol, the desorbing effect of urea was mitigated and in 
consequence the washing of contaminants was not successful. Contrary to what it was 
obtained, previous studies showed that the combination of 1.5 M urea and 5% glycerol 
is a possible strategy to form a washing buffer to have an increase in the protein purity 
level by HIC 
[51]
. 
Finally, analyzing and comparing the effect between control buffer (W0) and 
distilled water (W1), is evident that although the removal of contaminants is not 
optimal, the effect of washing water is positive because it allows to obtain a removal of 
some contaminants and a reduced elution of the protein in the washed samples as 
indicated by a red arrow in the Figure 27. Thus, face to this result, it was chosen a 
combination of the two buffers (W0 and W1) to try to purify by HIC technique the 
washed samples previously obtained from the application of W0,W2 and W3 buffers – 
samples of lanes 2, 4 and 5. Eluted fractions resulting from this test are shown in the 
SDS-PAGE gel shown in Figure 28. 
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Figure 27: 15%-4% SDS-PAGE gel with samples of HIC purification performed with different 
wash buffers: 1 – protein sample charged into the column; 2 - washed sample of WO; 3 - washed sample 
of W1; 4 - washed sample of W2; 5 - washed sample of W3; M - PageRuler™ protein marker 
(Fermentas). 
 
Figure 28: 15%-4% SDS-PAGE gel with samples of HIC purification performed with wash buffers 
W0 and W1: M – PageRuler™ protein marker (Fermentas); 1-7- eluted samples. 
 
This step of combining W0 and W1 buffers shows encouraging results in 
relation to purity level of final eluted fractions. With the exception of the eluted protein 
fraction present in lane 2, it is evident the reduced level of contaminants and it 
represents an important result in the purification of the fusion protein by HIC. This 
optimization of HIC washing was incorporated as part of the downstream purification 
process for this recombinant protein and offered tremendous advantages in terms of 
minimizing the number of column steps.  
With the performance of these purification strategies using the FH8 tag/HIC as 
purification technique, important guidelines were found for the purification of 
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FH8BMP-2 protein under native conditions. Thus, the addition of calcium has a 
predominant effect to increase specificity in the interaction with the hydrophobic resin, 
allowing for a good purity level and high final yield of recombinant protein. 
Additionally, a combination of washing buffers, such as distilled water, can have an 
important role in the process of removing contaminants which have some affinity with 
the resin. 
 
3.4.3 Ion exchange chromatography 
 
The use of anion exchange chromatography in the purification of protein 
FH8BMP-2 has two main purposes: firstly,  to understand if this technique can be used 
as a polishing technique after completion of a first purification step by HIC; secondly, 
with the use of an anionic exchanger, to find some explanations about net surface 
charge and conformation of fusion protein. 
Diagram of Figure 29 illustrates the steps that were executed in this stage of 
work. 
 
 
Figure 29: Illustrative diagram of steps performed in IEX procedure. 
 
The isoelectric point (pI) of FH8BMP-2 protein expressed using the vector 
pETM is 8.35 and the pH of the buffers used was 8.0. Thus, since the pH is slightly 
lower than the pI, the protein has a neutral or an overall minor positive charge. 
Therefore, an interaction between the fusion protein and in IEX column is not expected, 
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and so, it is anticipated to collect the protein in the flowthrough sample, free of 
contaminants. The aim is to elute contaminants through the NaCl gradient, according to 
their interaction with the resin, and thereby obtain a protein clean of impurities. 
However, analyzing the results obtained after passing the sample through the 
column of anion exchange purification, a different outcome was obtained from what it 
was expected. The protein has interacted with the anionic resin and therefore was 
recovered in eluted samples (data not shown). Taking the obtained result, it was made 
an extensive study of individual characteristics of surface charge of FH8 tag and BMP-2 
protein. So, starting with BMP-2 protein, a study of crystal structure of human BMP-2 
shows that pronounced charged regions are located at the fingertips regions of this bone 
morphogenetic protein where strong negative potential is visible and in the centre of the 
molecule exists two patches of mixed charge. On the other hand, this analysis shows 
that a high concentration of positive charges is localized at the N-terminal region 
[11]
. 
The cloning process followed in this work leads to fusion of FH8 tag to the BMP-2 N-
terminal sequence. Analyzing the main properties of the FH8 tag, it is possible to 
identify a pI of 5.60 and an overall negative charge. Thus, taking into account the 
properties of this calcium binding protein and its location in the fusion protein, it is 
possible to note that FH8 tag is in some way preventing the exposure of positively 
charged regions presented in BMP-2 protein and, in turn, it is favoring the exposure of 
its negatively charged residues. According to an analysis of FH8 tag and contrarily to 
the same aligned regions of other characterized calcium binding proteins, it was 
observed a region clearly negatively charged and a less hydrophilic area 
[38]
. This 
accessibility of negatively charged residues of FH8 tag allows a correspondence with 
the results obtained with the HIC purification technique and addition of calcium. That 
is, it was observed a strong interaction of the fusion protein with the hydrophobic resin, 
mediated by the binding of calcium to FH8 tag; this binding to calcium ions occurs in 
turn by the interaction with negatively charged residues of the tag FH8. These two 
results converge to the same findings in relation to the exposed regions of FH8 tag, in 
global fusion protein, to the purification resin.  
 
Taking into account the results presented from production and purification 
strategy studied in relation to fusion protein in pETM vector, it is possible to conclude 
that:  
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 The FH8 solubilises BMP-2 protein and it was proved to be a solubility 
tag with this target protein. 
 The HIC technique via the FH8 tag, similarly to what happens to fusion 
protein in pQE-30 vector shows good results in purification profile of the target 
protein, when combined with calcium addition to soluble fraction. 
 Calcium ions have an important role in reducing retention of unspecific 
proteins from hydrophobic resin, through conformational changes in structure of 
FH8 tag and by influencing adsorption mechanisms of BMP-2 to the 
hydrophobic resin. Additionally, this reagent potentiates aggregation of fusion 
protein leading to a dimeric form. So, in presence of calcium, the possible 
dimerization of BMP-2 together with the exposure of hydrophobic regions of the 
FH8 tag can explain the strong interaction between fusion protein and HIC resin. 
 Finally, the yield of purified protein was much higher than the 
one obtained with the pQE-30/FH8BMP-2 recombinant protein. 
 The ion exchange and nickel affinity chromatography purification 
steps allows to support and to clarify the results obtained with HIC, by given 
indications of surface net charge and accessibility of histidines tail in the global 
conformation of fusion protein. 
 
3.5 Larger scale production and purification tests of soluble 
recombinant FH8BMP-2 in pStaby1.2 system 
 
In the larger scale production of the fusion protein in the vector pStaby1.2 it was 
not possible to obtain an objective analysis on the soluble expression. Production tests 
were performed under the same conditions that were made with the fusion protein 
cloned into the vector pETM. However, the amount of soluble protein obtained was 
very low, and purification tests were inconclusive. To conduct further study on the 
expression of the fusion protein in pStaby1.2 system, new strategies should be studied 
to obtain higher protein solubilisation and thereafter move to the purification strategies 
followed in the earlier systems studied (pQE-30 and pETM vectors). 
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Chapter 4: Main Conclusions and suggestions for forthcoming 
work 
 
The main objective of the present work was the optimization of the soluble 
production and purification of recombinant BMP-2 in E. coli.  
One major disadvantage of using E. coli as a host is that heterologous proteins 
are often expressed as insoluble aggregates of folding intermediates known as inclusion 
bodies. Insoluble recombinant proteins, generally, do not have activity because they 
lose their native conformation and therefore they can’t be used for applications in which 
such requirements are essential (biomedical applications). In previous reports, 
production of recombinant BMP-2 was achieved in bacterial inclusion bodies 
[5,16,17,19,20]
. 
To date, important tools have been developed to overtake this strong limitation, 
such as the use of fusion tags that enhance the solubility of expressed proteins.  
In this work, it was performed the soluble expression of recombinant BMP-2 
protein, a protein that is expressed in insoluble form in E. coli, using the fusion partners 
technology with FH8 tag. In this way, three different vectors (pQE-30; pETM and 
pStaby1.2) were used in order to test the soluble expression of the recombinant fusion 
protein, FH8BMP-2.  
The main results of production and purification of recombinant fusion protein 
allowed to conclude that: 
 The FH8 allows the solubilisation of BMP-2 protein in all the 
three vectors, so a new approach was developed to obtain bone morphogenetic 
protein in soluble form; 
 The cloning process of bmp-2 gene in pETM system resulted in a 
significant increase in soluble expression levels; 
 The soluble expression of the recombinant fusion protein in 
pStaby1.2 system translates into an important advantage since this is a system 
without the use of antibiotics, but it is still necessary improve soluble expression 
levels; 
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 It was not possible to purify recombinant fusion protein by 
IMAC-Ni, revealing that conformation of FH8BMP-2 might be promoting the 
exposure of FH8 tag instead of the histidines tail. 
 On the other hand, a new purification strategy by FH8/HIC 
technique was developed, which resulted in a high yield of purified protein in 
the pETM system. 
 The effect of calcium, in the purification process of the 
recombinant fusion protein by HIC, was determinant, since it promoted the 
reduction of binding of non-specific proteins to the hydrophobic resin through 
conformational changes in the structure of the FH8 tag. Additionally, the 
dynamic structure and behaviour characteristics of FH8 tag in the presence of 
calcium reflects the results obtained in relation to the aggregation of the fusion 
protein into a dimeric form. All these factors explain the strong interaction 
between fusion protein and HIC resin; 
After completion of this work and given the results obtained, interesting 
proposals can be made for future work. It would be interesting to assess the biological 
response induced by the protein BMP-2 with the FH8 tag and after tag removal, in order 
to verify if the tag has influence in the biological activity of the target protein.  
Another perspective would be the study of biomaterials that can be used as 
carriers for the delivery of BMP-2. The main role of a delivery system for BMP-2 is to 
retain this osteoindutive component at the site of injury for a prolonged time, providing 
an initial support to which cells attach and form regenerated tissue 
[52]
. This concept is 
an important step to the development of biomedical applications of bone morphogenetic 
proteins. 
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Chapter 6: Appendixes 
Appendix 1: Detailed composition of chemical products, solutions and 
reagents 
Table A1: Composition of solutions used in the project. 
LB-medium 
 
10 g/L NaCl 
5 g/L Yeast extract 
10 g/L Tryptone 
Adjust pH to 7.5 with NaOH 10N 
LB-antibiotic plate 
 
LB-medium 
2% (w/v) Agar 
Final concentrations of antibiotics 
Ampicillin: 50 µg/ml 
Kanamycin: 50 µg/ml 
Chloroamphenicol: 33µg/ml 
Super Optimal Broth (SOB 
Medium) 
 
Tryptone            2 % 
Yeast Extract  0.5 % 
NaCl    10 mM 
KCl   2.5 mM 
MgSO4    10 mM 
MgCl2    10 mM 
Super Optimal broth with 
Catabolite repression (SOC 
Medium) 
SOB medium with 20 mM Glucose. 
Prepare 1 M Glucose solution (180 g/L) and filter sterilize. 
Store at 4 ºC. 
Add 200 μL of this solution to 9.8 mL SOB 
TB solution 
 
10 mM PIPES or HEPES 
15 mM CaCl2 
250 mM KCl 
Dissolve in milliQ water and adjust pH to 6.7 with KOH or HCl and then 
add 55 mM MnCl2 and adjust to final volume 
Sterilize by filtration with 0.2 µm filter and store @ 4°C 
TAE buffer 
40 mM Tris-acetate 
2 mM EDTA 
 
DNA 5x sample loading dye 20 mM EDTA 
25% Glicerol 
10x running buffer  SDS-
PAGE 
17.7 mM Tris-HCl 
0.25(w/v) SDS 
0.2 M Glycine 
5x loading sample buffer SDS-
PAGE 
0.15 mM TrisHCl pH6.8 
10% (w/v) SDS 
50% (v/v) Glycerol 
25% (w/v) β-mercapitalethanol 
0.01% (w/v) bromophenol blue 
10x PBS solution 
80 g/L NaCl 
2 g/L KCl 
2.4 g/L KH2PO4 
17.80 g/L Na2HPO4.2H2O 
adjust pH to 7.4 with HCl 
Coomassie Blue solution 
Dissolve in 1L of distilled water 60-80 mg de Coomassie Brilliant Blue 
G250; 
Stir the solution with a magnet for 2 to 4 hours at RT; 
Add 3 ml of concentrated 37% HCl solution; 
Store the reagent at RT environment, protected from the light 
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Appendix 2: Hidrophobicity analysis of FH8BMP-2 using Kyte and 
Doolittle scale 
 
The hidrophobicity analysis was made by the tool ProtScale available at the 
platform Expasy, using Kyte and Doolittle scale. In this scale, regions with a negative 
score correspond to hydrophilic regions of the protein sequence. Those presenting a 
positive score are hydrophobic regions. The analysis of Figures A1 and A2 
demonstrates that the protein FH8BMP-2 expressed using both pQE and pETM vector 
systems is predominantly hydrophilic, with only one hydrophobic region in the case of 
pQE-30/FH8BMP-2 and two hydrophobic regions in the case of pETM/FH8BMP-2. In 
the hydrophilic domain stands an extremely hydrophilic region (close to position 100 
identified in Figures A1 and A2). 
 
 
Figure A1: Analysis of the hydrophobicity of pQE-30/FH8BMP-2, according to the Kyte and Doolittle 
scale. 
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Figure A2: Analysis of the hydrophobicity of pETM/FH8BMP-2, according to the Kyte and Doolittle 
scale. 
 
 
Appendix 3: Neb-Cutter analysis 
 
In Table A2 is part of the list of enzymes that do not cut the fragment bmp-2 to 
be amplified by PCR. As can be seen, the enzymes NcoI, SacI and XhoI are included in 
this list. 
Table A21: List of enzymes that do not cut the bmp-2 fragment. 
Enzymes that don´t cut 
NcoI 
NdeI 
NgoMIV 
NhaXI 
NheI 
SacI 
SalI 
SapI 
Sau96I 
SbfI 
ScaI 
XcmI 
XhoI 
XmaI 
XmnI 
ZraI 
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Appendix 4: BLASTN analysis of the sequencing results of 
pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2 clones 
 
After performing a manual analysis of the sequencing results, sequences 
corresponding to BMP-2 and FH8 proteins were analyzed using the software tool 
BLASTN (http://www.ncbi.nlm.nih.gov/BLAST) and the results are presented in Figure 
A3. As can be seen, there is a corresponding match of 100% with the sequence of BMP-
2 protein from human origin and with FH8 sequence from the organism Fasciola 
hepatica. 
 
Figure A3: BLASTN analysis of pETM/FH8BMP-2 and pStaby1.2/FH8BMP-2 clones. 
 
To confirm the existence of EF-hands in the FH8 fusion protein, there was made 
a computer analysis of the domains of the fusion protein tag. This was performed using 
the software of the NCBI conserved domain search, which proved the existence of 
domains expected for the fusion protein FH8BMP-2. 
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 Figure A4: Results of the analysis of protein domains in fusion conserved domain by NCBI software. 
 
 
 
 
 
 
 
